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CHAPTER I
INTRODUCTION
Cell Adhesion and Metastasis
 It is estimated that 25% of all deaths in the United States are attributed to 
cancer-related events (1). Despite significant advances in cancer therapy, the 
primary cause of morbidity  and mortality of cancer is attributable to the departure 
of tumor cells from their primary  site to distant sites and the resistance of these 
metastatic tumors to current therapies. In the process of tumor cell dissemination 
to distant sites, tumor cells assimilate normal cell migration processes (2). Modu-
lation of cell adhesion molecules is a key functional component involved in the 
metastatic process, a complex cascade involving: 1) detachment from the pri-
mary site 2) invasion of the extracellular matrix, 3) intravasation and dissemina-
tion via haematogenous or lymphatic routes 4) extravasation and migration to 
target tissues and 5) establishment of a tumor at a secondary site (3). In the early 
steps of tumor cell detachment from the primary site, epithelial tumor cells un-
dergo dramatic changes leading to the acquisition of a motile phenotype through 
epithelial-to-mesenchymal transition (EMT) and subsequent changes in intracel-
lular adhesion (4). Tumor cell migration is dependent on a dynamic regulation of 
adhesion and de-adhesion, reiterating the requirement cellular plasticity  of adhe-
sion molecules to facilitate metastatic dissemination (5).
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 Cell adhesions predominantly function through three main types of cell 
adhesion molecules (CAMs): cadherins, claudins and immunoglobulin-like cell 
adhesion molecules (Ig-CAM). Of the three classes of adhesion molecules, the 
Ig-CAMs are likely to regulate the most diverse array  of cellular functions critical 
to tumor progression and metastasis (Table I; (6)).  Ig-CAMs are characterized by 
a variable number of extracellular immunoglobulin domains and fibronectin type 
III repeats (7). While most contain a single-pass transmembrane domain and cy-
toplasmic tail, some are linked to the cell surface through a glycosylphosphatidy-
linositol anchor (8). Family members include melanoma cell adhesion molecule 
(MCAM), L1CAM, activated leukocyte CAM (ALCAM), intercellular CAM-1, neural 
CAM (NCAM), vascular CAM-1 (VCAM-1) and platelet endothelial CAM-1 
(PECAM-1). These compromise a diverse group  of adhesive receptors funda-
mental to biological functions ranging from maintaining tissue architecture, estab-
lishing homeostasis, controlling cell differentiation, and mediating intracellular 
communication (6). Consequently, they participate in almost every physiology 
and pathology including neural development, cellular migration, and tumor cell 
biology. Not only do immunoglobulin superfamily (Ig-SF) cell adhesion molecules 
exert their functions through cell-cell and cell-matrix adhesion, they  are also able 
to elicit signals that function in tumor progression. Neural cell adhesion molecule 
(NCAM) is known for its role in neurite outgrowth, axonal guidance and long term 
potentiation (9). This prototypical immunoglobulin superfamily cell adhesion 
molecule (Ig-SF CAM) is known to initiate intracellular communication through 
activation of fibroblast growth factor receptor (FGFR) or through direct interaction 
2
Table 1. Summary involvement of Immunoglobulin Superfamily  (Ig-SF) cell ad-
hesion molecules in the metastatic cascade. 
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Involvement of IgSF Members
Stages in Metastasis Known Role Potential Role
(1) Cell Proliferation in Primary Tumor
          (i) Apoptotic Evasion
NCAM, ALCAM, 
PECAM-1, ICAM-1
MCAM
          (ii) Angiogenesis PECAM-1, ICAM-1 VCAM
(2) Local Cell Invasion
          (i) Cell-Cell Interactions MCAM, L1CAM, ALCAM
          (ii) Directional Cell Migration & Polarity MCAM
ICAM, VCAM, PECAM-1, 
NCAM, MCAM, L1CAM
          (iii) Matrix Degradation MCAM, NCAM ALCAM
(3) Invasion and Dissemination MCAM, ALCAM
(4) Extravasation
MCAM, ALCAM, NCAM, 
L1CAM, PECAM-1
(5) Colonization and Proliferation As for (1) and (2) As for (1) and (2)
(6) Immunological Escape MCAM, ALCAM, NCAM 
Adapted from Wong et al., International Journal of Cell Biology 2012
with its cytoplasmic domain with tryosine kinases, Fyn and Fak (10), resulting in 
sustained MAPK activation and cell migration (11). Not only is NCAM-dependent 
FGFR signaling required for in vitro epithelial ovarian cancer cell migration and 
invasion, NCAM expression is clinically correlated with advanced epithelial ovar-
ian cancer tumor grade (12). Studies in endothelial cells overexpressing the Ig-
SF CAM, PECAM-1, have shown a reduction in migration. In contrast, expression 
of the nonphosphorylateable PECAM-1 increased endothelial cell migration, sug-
gesting divergent functions of the intra- and extracellular domains. PECAM-1 in-
tracellular domain associates with SHP-2, a tyrosine phosphatase, to signal 
changes in phosphorylation of cytoskeletal and focal contact components, high-
lighting the non-adhesive functions of Ig-CAMs in modulating cellular and mo-
lecular behavior (13). On a clinical level, a number of Ig-SF members have been 
identified as biomarkers of advanced tumor progression, thus understanding the 
molecular interactions of cell adhesion molecules are critical to understanding 
metastatic tumor progression.
General Introduction to ALCAM and its cellular functions
Activated Leukocyte Cell Adhesion Molecule (ALCAM)
 ALCAM (activated leukocyte cellular adhesion molecule) is a cell surface 
glycoprotein and immunoglobulin superfamily (Ig-SF) member frequently referred 
to by its cluster of differentiation (CD) annotation, CD166. Major sites of ALCAM 
expression include most epithelial cells, hematopoietic cell populations (particu-
larly activated T-cells), the central nervous system, endothelial cells, and most 
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stem cell populations. ALCAM belongs to a small subgroup  of the Ig-SF, defined 
by five extracellular immunoglobulin-like domains, including two variable (V) and 
three constant (C) domains (VVC2C2C2). The membrane distal variable region is 
the ligand-binding domain while the membrane proximal constant regions are re-
sponsible for homotypic oligomerization (Fig. 1) (14). ALCAM is a cell–cell adhe-
sion protein that can engage in homophilic (ALCAM–ALCAM), and heterophilic 
interactions with CD6 (ALCAM–CD6). Although initially identified and primarily 
expressed in activated leukocytes as the only known ligand for CD6, ALCAM is in 
fact broadly expressed in human tissues and cells, including neuronal, immune, 
epithelial, and stem cells of hematopoietic and mesenchymal origin. ALCAM par-
ticipates in a number of cellular response mechanisms, including T-cell activation 
and proliferation, angiogenesis, hematopoiesis, and axon fasciculation. Pathol-
ogically, ALCAM expression and function have been associated with a number of 
cancers, including melanoma, prostate cancer, breast cancer, and colorectal car-
cinoma. The broad biological impact of ALCAM has led to various alternate 
names, including MEMD, SC-1, DM-GRASP, BEN and CD166. While its capabil-
ity as an adhesion molecule is clear, the molecular mechanism and function of 
ALCAM remain unclear. Recent studies in models of tumors and neuron devel-
opment suggest that it has roles in cell differentiation and vascularization, as well 
as invasion and migration.
 On the cell surface in the blood–brain barrier endothelium, ALCAM is con-
centrated in cholesterol-enriched microdomains, or lipid rafts (15). In highly spe-
cialized lung microvascular endothelial cells, ALCAM is localized to the adherens 
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Figure 1. ALCAM adhesion and proteolytic regulation. (i) Oligomerization 
domain of ALCAM is located at the D3-5 membrane proximal region (ii). Homo-
typic interactions are mediated through engagement of the terminal amino-D1 
domain (iii) ADAM17/TACE is an metalloprotease involved in the processing of 
ALCAM resulting in the cleavage and release of extracellular ALCAM 
junctions, and participates in a complex containing vascular endothelial (VE) 
cadherin and neural (N) cadherin (16). ALCAM is continuously recycled through 
endocytic pathways and is readily detectable in early endosomes. On the cell 
surface, ALCAM co-localizes with clathrin, but not caveolin-1 (17). In several 
neoplasia, ALCAM overexpression is associated with diffuse cytoplasmic staining 
(18-20). 
 ALCAM functions as a cell–cell adhesion molecule and engages in homo-
typic (ALCAM–ALCAM) and heterotypic (ALCAM–CD6) interactions between ad-
jacent cells. These interactions are mediated through its most amino-terminal V 
domain (D1). In ALCAM-ALCAM interactions this seems to be a D1–D1 interac-
tion (21,22), while in ALCAM–CD6 interactions the ALCAM D1 domain binds to 
the membrane-proximal scavenger receptor cysteine rich (SRCR) domain of CD6 
(Bowen et al., 1996). ALCAM is also capable of oligomerizing through lateral in-
teractions between adjacent ALCAM molecules in the same cell. These interac-
tions occur through the D3–D5 domains proximal to the membrane (22). ALCAM 
expression is most apparent at areas of cell–cell contact, where it may interact 
with other cell–cell adhesion molecules. In fact, upon reconstitution of the α-
catenin/E-cadherin complex by  α-N-catenin transfection, ALCAM relocalizes to 
the cell membrane and co-localizes with E-cadherin at the cell membrane in 
prostate cancer cells. In addition, these cells reverted to an epithelial-like mor-
phology (23) further defining a functional role for ALCAM in cell–cell adhesion. 
The amino-terminal V-type Ig domain is required for cell–cell adhesive interac-
tions and is, in fact, expressed as an isolated, alternatively spliced isoform (24).
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 While the participation of ALCAM in several biological processes has been 
verified, the exact molecular mechanism remains unclear. The highly conserved 
nature of the short cytoplasmic domain suggests that ALCAM functions, in part, 
by conveying extracellular signals to the cytoplasm. In spite of the participation of 
ALCAM in many  biological processes, ALCAM knockout mice have been gener-
ated and are viable, fertile. These mice exhibit no defects in fertility, nor any out-
ward physiological defects, and have normal organ development and a normal 
lifespan (25). However, upon detailed analysis, an axon fasciculation defect and 
a neuromuscular synapse defect have been identified (26). It seems that ALCAM 
is required for targeting retinal axons to their termination zones in two brain tar-
gets: the superior colliculus and the lateral geniculate nucleus (26).
ALCAM in hematopoietic cells
 ALCAM received this name when it was identified in activated leukocytes 
as the only known ligand for CD6 (27), and the ALCAM–CD6 interaction is re-
quired for optimal activation of T-cells (28-31). In vitro affinity and kinetic binding 
analysis revealed a 100-fold weaker homophilic interaction compared to CD6-
ALCAM heterotypic interaction. Moreover, ALCAM plays a critical role in mediat-
ing the transmigration of T-cells and monocytes across the blood–brain barrier 
(15,32). Through its heterotypic interaction with CD6, ALCAM seems to be impor-
tant for formation of the immunological synapse at the T-cell:antigen-presenting 
cell (APC) interface during antigen presentation (33). In fact, optimal T-cell activa-
tion requires CD6–ALCAM engagement (29,34). Moreover, unlike other adhesion 
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molecules in the immunological synapse, ALCAM is required for the whole proc-
ess of T-cell activation (31). 
Role in Development
 ALCAM is expressed in human blastocysts, but not in embryos at the 8-
cell or morula stages. ALCAM expression reappears in most developing tissues 
(35-38). Nevertheless, the adhesive role of ALCAM is apparent in development, 
where the loss of ALCAM function results in loss of cell adhesion and cardiac 
morphogenesis in the Xenopus model system (39). Using injection of morpholi-
nos targeting ALCAM into zebrafish, coupled with rescue experiments expressing 
ALCAM mRNA, Choudhry and colleagues determine that ALCAM is essential for 
ventral cartilage development (40). In this same study, endothelin-1, a known mi-
togenic peptide in several cancers, was able to modulate ALCAM expression 
through stabilization and prevention of proteosomal degradation. ALCAM func-
tions in hematopoietic and endothelial development and is highly associated with 
hematopoiesis and vasculogenesis (41). Neuronal outgrowth studies in chick and 
zebra fish further define ALCAM as a guidance protein for cellular migration and 
neuronal outgrowth during development (35,42,43).
Expression in multipotent and stem cells
 Although ALCAM was initially used to delineate hematopoietic stem cells 
(44), the molecule has been used broadly  as a surface marker (under the name 
CD166) in a panel of markers (including CD44, CD90, CD105, CD73, CD29 and 
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CD133) to define multipotent cells from a variety of tissues, including umbilical 
cord blood (45), bone marrow (46), testes (47), fetal lung (48), intervertebral disc 
(49), and dental pulp (50). More recently, the expression of CD166 as a marker of 
cancer stem cells has become of significant interest (51-54). While ALCAM is 
clearly  a defining feature of stem cells, it is unclear if there is a functional contri-
bution to the multipotent capacity of these cells.
ALCAM in the neural network
 The abundance of ALCAM in neuronal tissue is reflected in its sequential 
discovery in neurons and related tissues from various species as DM-GRASP 
(55), SC-1 (21), neurolin (56), and BEN (57). ALCAM controls the extension of 
axons (43,58-60) and is involved in axonal guidance and mapping (26,61). While 
ALCAM knockout mice are outwardly normal in appearance, they do have 
physiological deficiencies, including a delay in maturation of neuromuscular junc-
tions and defects in axon fasciculation (25,26). ALCAM-blocking antibodies in-
duce aberrant branching in zebra fish motor axons during development (43). Dur-
ing in vitro experiments axon outgrowth can be guided by ALCAM-coated sur-
faces, thereby providing conclusive evidence of ALCAM as a migration-guiding 
factor (58,59).
Interactions with Ligands and other proteins
 In addition to the well established homophilic interactions, ALCAM was 
identified as the only known ligand for CD6, a member of the SRCR protein su-
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perfamily  (22,27). In contrast with the relatively  weak and transient homophilic 
ALCAM–ALCAM interactions, ALCAM–CD6 interactions are robust and persis-
tent (34,62). These interactions are thought to be important for T-cell proliferation 
and maturation (31). In both instances it is the amino-terminal V domain that is 
engaged in the protein–protein interactions. For neuronal guidance, ALCAM has 
been suggested to interact with L1CAM (L1-cellular adhesion molecule, also 
known by the chick homolog NgCAM). This interaction seems to target retinal 
axons during development (26,58,63).
 ALCAM co-localizes with E-cadherin through an α-catenin-dependent 
process, although no direct interaction has been confirmed (23). ALCAM also re-
quires active protein kinase C alpha (PKC-α) for ALCAM-mediated cell adhesion 
(64). While no physical association between these proteins has been confirmed, 
ectopic expression of in K562 leukemic cells activates PKC, leading to cell clus-
tering (65). Association with the actin cytoskeleton is confirmed and regulates 
ALCAM clustering. Though interactions that connect ALCAM to the cytoskeleton 
are unknown (62,66), preliminary findings from Sawhney et al. (19) suggest the 
scaffolding proteins 14-3-3ζ and 14-3-3σ may be involved.
 Though little is known about the cytoplasmic tail, it has been shown to be 
ubiquitinated. Ubiquitination seems to control ALCAM endocytosis and thereby 
affect its role in axon navigation (67). ALCAM was also shown to interact with 
EGFR (68); however, this observation was made in an epidermoid carcinoma cell 
line (A431) and has not been confirmed elsewhere. Recently, ALCAM was shown 
to specifically bind galectin-8 sequestered in the extracellular matrix (69). This 
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interaction influenced endothelial cell migration and tubule morphogenesis. Anti-
ALCAM antibody studies suggest that this interaction involves the same domain 
that is required for homotypic ALCAM–ALCAM, as well as CD6, binding.
ALCAM in the bone marrow
 ALCAM was defined initially as a hematopoietic cell antigen present in 
bone marrow (70,71). Indeed, ALCAM is a surface marker of the earliest hema-
topoietic precursor populations, the mesenchymal stem cells, and stromal cell 
populations present in the bone (72-74). Along with CD90 and CD105, ALCAM 
defines a multipotent progenitor cell population capable of chondrogenic, osteo-
genic and adipogenic differentiation (75-77). Early observations by Bruder et al. 
indicated a functional role for ALCAM in the bone marrow. They determined that 
anti-ALCAM fragment, antigen binding (Fab) fragments promote osteogenic dif-
ferentiation (72). Indeed ALCAM delineates subpopulations of the endosteal 
niche, where its expression defines populations of mature osteoblasts and mes-
enchymal stem cells (74,78,79). In particular, Chitteti et al. defined mature osteo-
blasts specifically as CD45-CD31-Ter119-Sca1-ALCAM+ (79).
Subcellular localization and Regulation of Activity
 On the cell surface in the blood–brain barrier endothelium, ALCAM is con-
centrated in cholesterol-enriched microdomains, or lipid rafts (15). In highly spe-
cialized lung microvascular endothelial cells, ALCAM is localized to the adherens 
junctions, and participates in a complex containing vascular endothelial (VE) 
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cadherin and neural (N) cadherin (16). ALCAM is continuously recycled through 
endocytic pathways and is readily detectable in early endosomes. On the cell 
surface, ALCAM co-localizes with clathrin, but not caveolin-1 (17). In several 
neoplasias, ALCAM overexpression is associated with diffuse cytoplasmic stain-
ing (18-20).
 Since cell–cell adhesion is the primary activity of ALCAM, adhesive inter-
actions can be regulated by its availability  and ability to bind to proximal partners. 
ALCAM is dysregulated in a number of cancers, including, but not limited to, 
melanoma, colorectal, breast and prostate. Immunohistochemical analysis 
showed that ALCAM was overexpressed in low-grade carcinoma. However, in 
some high grade carcinomas ALCAM was either localized to the cytoplasm or 
lost altogether (18,80-82). Although there is differential ALCAM expression in 
cancer, the mechanism by which it is regulated is unknown.
 At the subcellular level, cytoskeleton disruption, via chemical treatment in 
erythroleukemic K562 cells with cytochalasin D, promotes lateral movement of 
ALCAM and promotes ALCAM-mediated adhesion regulated through 
cytoskeleton-dependent clustering (66), This effect suggests ALCAM clustering is 
necessary to form stable cell adhesion complexes (14,22).
ALCAM Shedding
 Similar to other cell adhesion molecules, ALCAM can be proteolytically 
shed from the cell surface. Currently ADAM17, a member of the disintegrin and 
metalloproteinase family, is the only known protease able to cleave ALCAM (Fig. 
13
1; (83)). ADAM17, initially identified as the enzyme cleaving TNFα from its trans-
membrane precursor form (84), is a promiscuous “sheddase” involved in cleav-
age of many other immunoglobulin superfamily cell surface proteins including 
ICAM-1 (85), VCAM-1 (86), NCAM (87), and L1CAM (88). Cleavage of ALCAM is 
thought to occur at the membrane proximal region, generating a soluble ALCAM 
component containing the five extracellular domains and a truncated membrane-
bound ALCAM containing the transmembrane and cytoplasmic domains. Prote-
olytic release of ALCAM can be induced by  non-specific agents, including phor-
bol myristate acetate (PMA) or ionomycin, and through epidermal growth factor 
receptor stimulation (89). It has been reported that inhibition of ADAM17 with 
CGS27023A inhibitor in TPC-1 cells results in a dose-dependent decrease in 
shed ALCAM in culture media (90). Interestingly, the expression of the soluble D1 
domain (sALCAM, the most amino-terminal V domain) (24) could potentially  dis-
rupt the interaction between full-length membrane-anchored ALCAM molecules 
(14), however it is currently  unclear how shed ALCAM can compete with cis or 
trans ALCAM-ALCAM interactions. ALCAM concentrations in the cell can be 
regulated by expression, endocytosis, and shedding from the cell surface. The 
studies presented here are some of the first to investigate the parameters that 
change ALCAM shedding and connect this biology with patient outcome.
ALCAM in cancer
 Cancer-associated ALCAM was first identified as MEMD in melanoma cell 
lines (91). ALCAM has subsequently been found to be expressed in almost all 
14
cancers, although it is distinctly absent in myeloma. Even though the pathological 
function of ALCAM is not fully understood, in vivo mouse studies demonstrate its 
participation in cancer progression (92-94). Truncation of ALCAM can be 
achieved by ADAM17 and may facilitate migration (89). Indeed the upregulation 
of truncated ALCAM that lacks the D1 domain (ΔN-ALCAM) promotes metasta-
sis, while the ectopic expression of soluble amino-terminal D1 (V) domain inhibits 
metastasis (Table 2, (14,93). The distinct up  regulation of ALCAM in some can-
cers but down-regulation in others has created a paradox in terms of its contribu-
tion to cancer progression (95). Histological analysis has emphasized that the 
cytoplasmic localization of ALCAM correlates more strongly with cancer progres-
sion than the overall expression level (18,19,81,96). Although somewhat contra-
dictory, recent research using blocking antibodies confirms that the presence of 
ALCAM can contribute to the metastatic process (96,97), while expression analy-
sis illustrates that the absence of ALCAM can convey resistance to treatment 
(98). It is likely that the role of ALCAM in cancer is context-dependent and its 
function is influenced by tissue from which the tumor originated.
 In recent years ALCAM expression has been used as a biomarker of can-
cer progression in prostate cancer (99), colorectal cancer (20), breast cancer 
(98,100-102), oral cancers (19), pancreatic cancer (96,103), neuroblastoma 
(104), ovarian cancer (81), gastric cancer (105) and melanoma (106). Serum 
levels of ALCAM have also been explored as a diagnostic tool for cancer (107-
112). The studies presented within this thesis explore the relationship between 
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ALCAM expression and ALCAM shedding while correlating these parameter to 
patient outcome (113).
Summary of Dissertation
 The dissemination of prostate cancer to bone is a common, incurable as-
pect of advanced disease. Prevention and treatment of this terminal phase of 
prostate cancer requires improved molecular understanding of this process as 
well as markers indicative of molecular progression. The goal of my dissertation 
research was to investigate the contribution of tumor-derived ALCAM in prostate 
tumorigenesis in vivo, and the clinical application of intratumoral ALCAM shed-
ding in colorectal cancer progression. 
 In Chapter II, I demonstrate, using biochemical analyses and in vivo loss-
of-function studies that the cell adhesion molecule ALCAM is actively shed from 
metastatic prostate cancer cells by the sheddase ADAM17 in response to TGFβ. 
Not only is this post-translational modification of ALCAM a marker of prostate 
cancer progression, the molecule is also required for effective metastasis to 
bone. Biochemical analysis of prostate cancer cell lines reveal that ALCAM ex-
pression and shedding is elevated in response to TGFβ signaling. Both in vitro 
and in vivo shedding are mediated by ADAM17. Longitudinal analysis of circulat-
ing ALCAM in tumor-bearing mice revealed that shedding of tumor, but not host-
derived ALCAM is elevated during growth of the cancer. Gene-specific knock-
down of ALCAM in bone-metastatic PC3 cells greatly diminished both skeletal 
dissemination and tumor growth in bone. The reduced growth of ALCAM knock-
17
down cells corresponded to an increase in apoptosis and decreased proliferation. 
Together these data demonstrate that the ALCAM is both a functional regulator 
as well as marker of prostate cancer progression.
 In Chapter III, we introduce the concept that molecular biomarkers of can-
cer are needed to assist histological staging in the selection of treatment, out-
come risk stratification, and patient prognosis. This is particularly  important for 
patients with early-stage disease. We demonstrate that shedding of the extracel-
lular domain of ALCAM (Activated Leukocyte Cell Adhesion Molecule) is prog-
nostic for outcome in patients with colorectal cancer (CRC). Previous reports on 
the prognostic value of ALCAM expression in CRC have been contradictory and 
inconclusive. This work clarifies the prognostic value of ALCAM by visualizing ec-
todomain shedding using a dual stain that detects both the extracellular and the 
intracellular domains in formalin-fixed tissue. Using this novel assay, 105 primary 
colorectal cancers patients and 12 normal mucosa samples were evaluated. AL-
CAM shedding, defined as detection of the intracellular domain in the absence of 
the corresponding extracellular domain, was significantly  elevated in CRC pa-
tients and correlated with reduced survival. Conversely, retention of intact AL-
CAM was associated with improved survival, thereby confirming that ALCAM 
shedding is associated with poor patient outcome. Importantly, analysis of stage 
II CRC patients demonstrated that disease-specific survival is significantly  re-
duced for patients with elevated ALCAM shedding (p=0.01, HR 3.0) suggesting 
that ALCAM shedding can identify patients with early stage disease at risk of 
rapid progression.
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 The current data relating to ALCAM in tumorigenesis span a little over a 
decade, however future studies will likely provide more mechanistic insight into 
the paradoxical function of cell adhesion molecules in cancer. ALCAM partici-
pates in a number of diverse roles in human pathology including stem cell main-
tenance, cellular migration, and suppression of apoptosis, all properties that can 
be co-opted by  tumor cells to facilitate cancer progression. The ultimate goal of 
this dissertation was to gain a better understanding of ALCAM’s role in tumor cell 
invasion and metastasis. Together, our data and previously published literature, 
strongly suggest ALCAM to be a contributor to cancer progression. Future stud-
ies using intratumoral ALCAM shedding as a biomarker would advance early 
stage screening for aggressive disease, potentially leading to the identification of 
high risk patients and providing an opportunity for effective treatments. 
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CHAPTER I I
ALCAM/CD166 IS A TGFβ  RESPONSIVE MARKER AND FUNC-
TIONAL REGULATOR OF PROSTATE CANCER METASTASIS TO 
BONE 
INTRODUCTION
Morbidity  and mortality  among prostate cancer patients is frequently  a result of 
metastatic dissemination to bone (114,115). To date there is no curative treat-
ment for skeletal metastasis. and this growth of tumor in bone results in bone 
loss, fractures, and pain (116). Even for patients with organ-confined disease, the 
method and rigor of clinical intervention is defined in large part by the risk of dis-
ease progression. For patients with skeletal events, survival from the time of di-
agnosis to time of death is approximately 3-5 years (117). Thus, clinical interven-
tion would greatly benefit from further understanding of the molecular mecha-
nisms that drive skeletal metastasis as well as molecular indicators that identify 
patients at risk of disease progression. Since cell motility  is an important con-
tributor to metastasis, the activation state of migratory mechanisms could be 
suitable for both therapeutic intervention as well as a biomarker of metastatic be-
havior.
 Tumor cell metastasis to distant sites, including bone, is a multi-step proc-
ess. Cancer cells must first detach from the primary tumor site and migrate lo-
cally to invade blood vessels. Thereafter, tumor cells intravasate into the blood-
stream and are attracted to preferred sites of metastasis through site-specific cel-
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lular and microenvironmental interactions (5,118). Activated Leucocyte Cell Ad-
hesion Molecule (ALCAM) is a cell adhesion molecule that engages in homotypic 
and heterotypic cell adhesion in a calcium-independent manner (22). It has been 
implicated in a number of adhesive and migratory behaviors including axonal 
guidance, leukocyte homing and cancer metastasis. It has been demonstrated 
that ALCAM can be proteolytically cleaved at the cell surface by ADAM17 caus-
ing the ectodomain to be shed. ALCAM shedding can be induced by ionomycin, 
PMA, and epidermal growth factors (89). Proteolytic cleavage/shedding of cell 
surface proteins is a common regulatory mechanism which can alter the function 
and localization of transmembrane proteins such as cell adhesion molecules, 
growth factors and growth factor receptors. This regulation can weaken cell ad-
hesion and destabilize adherens junctions as in the case of E-cadherin, through 
the loss of homotypic cell adhesion molecular interactions (119). The soluble 
shed ectodomain can act as an antagonist, thereby competing for membrane-
bound receptors or cell adhesion molecules. While these processes are impor-
tant in development, they have also been associated with tumorigenesis. Func-
tionally, expression of the truncated, trans-membrane fragment of ALCAM in BLM 
melanoma cells results in increased lung metastasis in vivo, while overexpres-
sion of a soluble extracellular ligand-binding fragment diminished metastases (for 
review see (94) and (120). Previous studies from our lab and others have inves-
tigated the clinical relevance of ALCAM expression and shedding in a variety  of 
human malignancies, including colorectal, breast, ovarian, thyroid and prostate 
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c a n c e r, h o w e v e r i t s r o l e i n t u m o r i g e n e s i s r e m a i n s u n c l e a r 
(80,81,90,113,121,122). 
 Elevated ALCAM expression in aggressive prostate cancer (99) together 
with its putative role in cell adhesion/migration (93,94) suggests that ALCAM is a 
molecular participant in prostate cancer metastasis. We hypothesized that ecto-
domain shedding of ALCAM is induced by cytokines present in the tumor micro-
environment and that its detection can be a marker of tumor progression. This 
work herein investigates ALCAM expression and shedding by ADAM17 in re-
sponse to cytokine stimulation through biochemical analyses while its contribu-
tion to skeletal metastasis is determined in a series of orthotopic, and experimen-
tal metastasis models. We have identified transforming growth factor-beta 
(TGFβ), a pleiotropic cytokine that regulates growth, cell motility, development 
and differentiation, as a driver of ALCAM expression and shedding. TGFβ  signal-
ing is frequently dysregulated in prostate cancer and is considered instrumental 
in the tumor microenvironment whereby  it influences both tumor progression and 
metastasis (123-126). Findings from these investigations provide important in-
sight not only into the molecular correlation between ALCAM and prostate cancer 
progression but also demonstrate that ALCAM is a key functional contributor to 
metastatic growth in the bone.
22
MATERIALS AND METHODS
Reagents, cell culture. Full-length purified recombinant porcine TGFβ was ob-
tained from R&D Systems . Antibodies against ALCAM were obtained from R&D 
Systems (Clone 105902). The following tumor cell lines were obtained from 
American Type Culture Collection (Manassas, VA) and maintained according to 
the American Type Culture Collection’s recommendations: DU145, LNCaP, PC3 
(prostate metastasis). PC3-luciferase (PC3-luc) cells (Dr. Ken Pienta, University 
of Michigan) were cultured in RPMI/10%FBS.
SDS-PAGE and immunoblotting. Cells (2.5 × 105) were plated in 6-well dishes. 
After 24 h, cells were serum starved in Opti-MEM for 16 h and then treated in the 
presence or absence of indicated growth factors or inhibitors, for 48 h. After that, 
the cells were lysed in TNE Lysis Buffer (20 mM Tris-Cl [pH 7.4], 0.5 mM EDTA, 
1% Triton X-100, 150 mM NaCl, protease inhibitor cocktail (Sigma), 1 mM phen-
ylmethylsulfonyl fluoride (PMSF). Total protein in the lysates was quantified using 
BCA assay (BioRad). Conditioned media samples were concentrated with micro-
con centrifugal filters (Millipore) following manufacturers protocol, which were 
eluted directly in 5X sample buffer for Western blot analysis. Protein loading for 
conditioned-medium samples for Western blot analysis was adjusted according 
to the total protein in cell lysates. Conditioned media and total protein was sub-
jected to SDS-PAGE and electrophoretic transfer to polyvinylidene difluoride 
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membranes (Immobilon P, Millipore, Inc., Bedford, MA). Immunodetection was by 
conventional chemiluminescence.
Quantitative PCR. The mRNA samples were prepared from tumor cells lysed in 
TRI Reagent (Ambion) and purified using phenol extraction, followed by real-time 
polymerase chain reaction (RT-PCR). The following qPCR primers were used 
ALCAM, TCAAGGTGTTCAAGCAACCA (forward) and CTGAAATGCAGT-
CACCCAAC (reverse); ADAM17, ATGTTTCACGTTTGCAGTCTCCA (forward) 
and CATGTATCTGTAGAAGCGATGATCTG (reverse); and glyceraldehyde-3-
phosphate dehydrogenase, ATCTTCTTTTGCGTCGCCAG (forward) and 
TTCCCCATGGTGTCTGAGC (reverse).
ShRNA Knockdown. To establish cell lines in which ALCAM expression is stably 
knocked down cells were transduced with ALCAM-specific “Mission” shRNA 
(Sigma) lentivirus. Following transduction, cells were selected in 10μg/ml of pu-
romycin. Transduced cells were flow sorted for ALCAM expression and ALCAM 
knock-down cells were cultured and maintained on 5μg/ml of puromycin.
Migration Assay. Two-dimensional gap closure assays (formerly  known as 
scratch assays) were conducted using magnetically attachable stencils attached 
to culture plates (127). In short, 250,000 cells were seeded in 6-well plates and 
allowed to recover overnight to form a confluent monolayer. Stencils were re-
moved with tweezers, after which cells were rinsed with PBS to remove detached 
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cells. Culture medium was re-added and closure of the gap was measured at 8 
and 16 hours. Gap  closure was quantified using TScratch (National Institutes of 
Health, Bethesda, MD, USA).
Mouse models of acute inflammation. All animal handling was performed in 
accordance with institutional guidelines and approved by the Vanderbilt Institu-
tional Animal Care and Use Committee. C57BL/6(SJL)-Tg(SMAD binding ele-
ment [SBE]/Tk-luc)7Twc/J mice (128), obtained from the laboratory of Harold 
Moses, MD (Vanderbilt University), were used at 16 weeks of age. These trans-
genic mice, referred to as SBE-Luc mice, express luciferase in response to acti-
vation of the Smad2/3-dependent signaling pathway. Mice were administered 
2mg/kg of LPS to induce an acute inflammatory response and bled via saphe-
nous vein at 0, 6, 24 hours and 1 week post-administration. 
Mouse models of wound-healing Wounding was performed on mice anesthe-
tized with isofluorane. In brief, the mouse backs were shaved, back skin and 
panniculus carnosus was pulled up, and a sterile standard biopsy punch tool was 
used to create two circular excisional full-thickness wounds of 6-mm diameter 
described previously (129). Mice were bled via saphenous vein at 0 hours (estab-
lish basal levels), 24 hours, one week and two weeks after wound initiation.  
In vivo ALCAM serum half-life. Serum was harvested from ALCAM wild-type, 
mixed background, mice and pooled. Combined serum collected from WT mice 
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was injected retrorbitally  in ALCAM KO mice (100μl/mouse). ALCAM KO mice 
were pre-bled via saphenous vein bleed, and then bled at 10 mins, 2 hours, 4 
hours, 24 hours and 48 hours (n=2/time point; total n=10). WT pooled serum was 
used as ELISA control to quantitatively determine ALCAM serum half-life.
Histological analysis of mouse tissue. Tumor-bearing tissue and bones were 
fixed in 10% formalin. Bone specimens were decalcified in 20% EDTA pH 7.4 for 
3-4 days at room temperature. Decalcified bone and tissue were dehydrated and 
embedded in paraffin. Tumor burden was confirmed in 5μm serial sections 
stained with H&E. Osteoclast were visualized using a standard Tartrate Resistant 
Acid Phosphatase (TRAP) protocol. All immunohistochemistry and immunofluo-
rescence on tumor sections involved antigen retrieval using a standard pH 6.0 
citrate buffer followed by blocking via incubation with 20% Aquablock (East Coast 
Bio). Immunofluorescence data was obtained using primary antibodies for AL-
CAM (1:1000; Leica Biosystems; Clone, MOG/07), Ki67 (1:500; Fisher, Clone 
SP6), Cleaved caspase-3 (1:200; CellSignaling, D175), and collagen I (1:1000; 
Sigma C2206) by incubation overnight at 4°C. Corresponding Alexa Fluor® sec-
ondary antibodies were used (1:1000; Invitrogen). Fluorescent imaging was 
completed on a Olympus BX61WI upright fluorescent microscope using Volocity 
Imaging Software.
ELISA of mouse serum and plasma. Blood was obtained via the saphenous 
vein; samples were collected in either the presence of EDTA as an anticoagulant 
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or a serum separator tube (Fisher Scientific) and were centrifuged at 1,500 rpm, 
4°C to remove cells. Plasma and serum samples were stored at −80°C until ana-
lyzed. Samples were analyzed for soluble mouse and human ALCAM using the 
R&D Systems DuoSet following manufacturers instructions. Briefly, ELISA plates 
coated with capture antibody were incubated overnight with 100 μl of sera diluted 
1:50. Capture ALCAM was detected with biotinylated antibody and peroxidase-
conjugated avidin followed by colorimetric detection at 450 nm.
Mouse models of prostate cancer and in vivo quantitation of tumor growth. 
All experimental protocols were approved by the Vanderbilt University Institu-
tional Animal Care and Use Committee. Orthotopic prostate xenografts were per-
formed according to Li et. al (130). Briefly, 5 x 104 PC3-luc cells were suspended 
in 30 μl of neutralized type I collagen and allowed to polymerize for 16 hrs at 
37°C before implantation into the prostate of 10 week old C.B-17/IcrHsd-Prkdc 
scid male mice (Harlan). Tumor growth was monitored weekly  by bioluminescent 
detection of luciferase expressing cells. For the xenograft model, sub-confluent 
PC3-luc cells were trypsinized, washed twice in PBS to remove serum, and then 
resuspended in HBSS at a concentration of 1 × 107 cells/ml. One hundred μl con-
taining 1 × 106 PC3 cells in a 50/50 mix of PBS and growth factor-reduced Matri-
gel (BD Biosciences) were injected subcutaneously into the right flank of 7-week-
old nude male mice (Harlan Laboratories; athymic Foxn1 nu/nu). Tumor growth 
was monitored weekly  by caliper measurements, and tumor volume in mm3 was 
calculated based on the following formula: Volume = (width)2 x length/2. PC3-
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luciferase shControl (Vector) or PC3-luciferase  shALCAM (KD2 or KD3) tumor 
cells (1×105) in a 10 μl volume of sterile phosphate buffered saline (PBS) were 
injected into the tibia of anesthetized 6-week-old nude male mice (Harlan Labora-
tories) Skeletal metastasis was performed as previously described by Park et. al. 
(131). Briefly, 1 × 105 PC-3-luc cells were injected into the left heart ventricle of 
male nude mice (Harlan Laboratories). Skeletal metastases were monitored by 
bioluminescent detection of luciferase expressing cells and formation of bone le-
sion by  X-ray. Whole animal luminescent imaging was performed with the IVIS™ 
system (Caliper Life Sciences, Hopkinton, MA). Luciferin (150 mg/kg in sterile 
PBS, Biosynth International, Itasca, IL) was delivered via intra-peritoneal injection 
10 minutes prior imaging. Living Image™ software (Caliper Life Sciences) was 
used to quantify the luminescence intensity. Blood was obtained via the saphe-
nous vein and collected in either the presence of EDTA as an anticoagulant or a 
serum separator tube (Fisher Scientific). Plasma and serum samples were stored 
at −80°C until analyzed. 
Micro computed tomography (μCT) analysis. For gross analysis of trabecular 
bone volume, formalin fixed tibiae were scanned at an isotropic voxel size of 12 
μm using a microCT40 (SCANCO Medical, Bruttisellen, Switzerland). The tissue 
volume (TV) was derived from generating a contour around the metaphyseal tra-
becular bone that excluded the cortices. The area of measurement began at 
least 0.2 mm below the growth plate and was extended by 0.12 mm. The bone 
volume (BV) included all bone tissue that had a material density  greater than 
438.7 mgHA/cm3.
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Radiographic Analysis. Beginning 1 week after tumor cell inoculation, tumor-
bearing animals were subjected to radiographic imaging. Radiographic images 
(Faxitron X-ray  Corp, Lincolnshire, IL, USA) were obtained using an energy of 35 
kV and an exposure time of 8 seconds. Osteolytic lesions were quantified bilater-
ally in the tibia, fibula, femora, humeri, and pelvis at the endpoint using x-ray im-
ages. Lesion area and lesion numbers were evaluated using image analysis 
software (Metamorph, Molecular Devices, Inc.). Data presented are the average 
of lesion area and lesion numbers per mouse in each group.
Statistical Analyses. Expression analysis was performed on datasets GDS1439 
andGSE10645 available through the Gene Expression Omnibus (references 
(132) and (133) respectively). Expression data for selected genes from GDS1439 
was clustered in software Cluster 3.0 and visualized with software TreeView. For 
survival analysis the patient population of GSE10645 (n=596) was dichotomized 
across upper and lower quartile of ALCAM expression. Statistics were completed 
using either R, SPSS or GraphPad Prism. For all standard bar and box plots the 
results were reported as mean and SEM unless stated otherwise in the legend. 
Comparisons were performed using unpaired two-sided Student’s t-test, non-
parametric Mann-Whitney test, or one-way ANOVA. R2 and P values were re-
ported from linear regression analysis of mouse data. All statistical tests were 
considered significant when p<0.05 where *  denotes p< 0.05, ** denotes p< 0.01 
and *** denotes p< 0.001.
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RESULTS
ALCAM gene expression is elevated in advanced prostate cancer and cor-
relates with poor patient outcome. Changes in ALCAM expression have been 
linked to patient outcome for several malignancies. In prostate cancer the corre-
lation of ALCAM expression and patient outcome are sometimes conflicting. Min-
ner et. al. (122) conclude that reduced ALCAM expression correlates to poor pa-
tient outcome while the opposite is suggested by Kristiansen et. al. (99). We 
evaluated several publicly available microarray datasets to determine the rela-
tionship  between ALCAM mRNA levels, patient diagnosis and outcome (Fig. 2). A 
comparison of benign, localized and metastatic disease revealed increased lev-
els of ALCAM mRNA in metastatic prostate cancer (Fig. 2A, GDS1439). Elevated 
levels of ALCAM coincided with molecular evidence of a pro-migratory  phenotype 
based on the decreased expression of E-cadherin and p120 concurrent with ele-
vated expression of N-cadherin (Fig. 2B). These observations were supported by 
survival analysis for a cohort of 596 prostate cancer patients (GSE10645) which 
revealed that high levels of ALCAM mRNA corresponded with poor patient out-
come. (Fig. 2C). Immunohistological staining of prostate cancer tissue microar-
rays available through the Human Protein Atlas (134) revealed that ALCAM is 
clearly  evident in normal, benign and malignant disease but is frequently absent 
from the tumor cell surface in advanced disease (proteinatlas.org, Fig. 2D).
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Figure 2: ALCAM is overexpressed in metastatic prostate cancer and cor-
relates with patient survival. (A) ALCAM expression levels were analyzed in 
publicly available dataset (GDS1439, n=19) of prostate cancer. Heat map (A) 
and corresponding relative expression (B) of ADAM17 (i) ALCAM (ii) N-cadherin 
(iii), p120 (iv) and E-cadherin (v) indicated by arrows. (C) Correlation of ALCAM 
expression to overall survival in a publicly available dataset (GSE10645) com-
posed of 596 prostate cancer patients. Kaplan-Meier survival curves represent 
the upper and lower quartile ALCAM expression. (D) Representative images 
from immunohistochemical staining of ALCAM membranous and cytoplasmic 
expression in benign to metastatic prostate cancer. Images obtained through 
The Human Protein Atlas.
TGFβ induces ALCAM expression and shedding. Since ALCAM shedding is 
associated with disease progression, we set out to determine if cytokines associ-
ated with cancer progression could promote ALCAM shedding in vitro. ALCAM is 
proteolytically  shed from PC3 cells (Fig. 3). Absence of the cytoplasmic tail con-
firms that the ectodomain is shed (Fig. 3A). Moreover, ALCAM is absent from 
PC3-derived exosomes, ensuring that the ectodomain is shed and not released 
with cell-derived microparticles (Fig. 3B). Since prostate cancer disseminates 
predominantly to bone we selected cytokines thought to be involved in this proc-
ess, including TGFβ. Of the 8 agents tested, only TGFβ was able to promote 
ALCAM shedding relative to overall total protein increase (Fig. 4A). To further ex-
plore the response to exogenous stimulation with TGFβ, ALCAM expression in 
PC3 cells was compared to ALCAM expression in LNCaP cells which are unable 
to respond to the cytokine possibly due to a lack in the TGFβ receptor type I or 
mutation of the TGFβ  type II receptor (135) (Fig. 4B and C). Quantitative RT-PCR 
analysis for ALCAM demonstrates that TGFβ was also able to induce ALCAM 
gene transcription in PC3 but not LNCaP cells (Fig. 4B). The cytokine also in-
creased levels of ALCAM protein expression and ectodomain shedding (Fig. 4C). 
Conversely, LNCaP did not respond to TGFβ, even though these cells express 
abundant ALCAM (Fig. 4C). TGFβ-induced expression in PC3 cells could be ab-
rogated with the small molecule inhibitor SB431542 (Fig. 4D, 10μM; Sigma) while 
TGFβ-induced ALCAM mRNA and protein expression could be restored in 
LNCaP cells when the cells were transfected with dominant-active TGFβ receptor 
type I (Fig. 4E&F). 
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Diluent - - + -
TGFβ - - - +
Lysate + - - -
WB: C-terminal 
ALCAM Ab
WB: N-terminal 
ALCAM Ab
Total CM + - - + - -
CM Supernatant - + - - + -
Exosome Pellet - - + - - +
TGFß - - - + + +
ALCAM
CD151
A B
Figure 3. ALCAM shedding in prostate tumor cells is not associated with 
microparticles. A)  Western blot analysis of ALCAM shedding in conditioned 
media of LNCaP and PC3 cells treated with or without 10ng/ml of TGFβ using 
antibodies specifically  recognizing the extracellular and intracellular domains. B) 
ALCAM shedding in response to 10ng/ml TGFβ after 48 hours as measured by 
Western blotting of ALCAM and CD151 (exosome marker) in PC3 tumor cell 
conditioned media. Conditioned media was ultracentrifuged to isolate exosome 
fraction; “Total CM” = total conditioned media, “CM Supernatant” = conditioned 
media supernatant without exosome pellet, “Exosome pellet” = exosome pellet 
resuspended in phosphate buffered saline. 
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Figure 4. Expression and shedding of ALCAM is increased in response to 
TGFβ . (A)  ELISA analysis of ALCAM shedding in concentrated conditioned me-
dia of PC3 cells treated with indicated exogenous cytokines. TGFβ, p<0.001 (B) 
Expression of ALCAM by RT-PCR fold change relative to GAPDH, glyceralde-
hyde 3-phosphate dehydrogenase in PC3 or LNCaP cells  treated with or with-
out 10ng/ml of TGFβ  for 48 hrs (C) Western blot analysis of shed ALCAM in the 
conditioned media and intact ALCAM in the cell lysate in LNCaP and PC3 cells. 
D) Western blot detection of ALCAM and Phosphorylated-Smad2 expression in 
PC3 cells treated with 10ng/ml TGFβ for 48 hrs. in the presence or absence of 
10μM SB431542, a TGFβ receptor tyrosine kinase inhibitor. (E) RT-PCR and F) 
Western blot analysis of ALCAM expression in LNCaP cells transfected with vec-
tor control or T204D, dominant active TGFβ type I receptor; *p<0.05, **p<0.01.
ALCAM shedding in vivo correlates with tumor progression. Published clini-
cal studies have demonstrated that circulating levels of ALCAM are frequently 
elevated in cancer patients (103,110). These studies suggest that ALCAM is shed 
by the tumor, however, there has been no experimental comparison of tumor and 
host ALCAM to demonstrate definitively that the elevated levels of shed ALCAM 
are derived from the tumor. To determine if tumor-derived ALCAM is the source of 
elevated circulating ALCAM, we used species-specific antibodies to monitor cir-
culating levels of both host (mouse) ALCAM and tumor (human) ALCAM longitu-
dinally during orthotopic and subcutaneous growth of PC3 cells (Fig. 5). The half-
life of human ALCAM in the circulation of its mouse host was determined to con-
firm that tumor-derived ALCAM could act as a stable biomarker in vivo (Fig. 6). 
Circulating ALCAM exhibits a 17hr half-life which is sufficient for monitoring its 
release from an endogenous tumor burden.
 Circulating levels of ALCAM were subsequently monitored on a weekly 
basis (Fig. 5A) in SCID mice bearing subcutanous (Fig. 5B, n=5) or orthotopic 
xenografts of PC3 (Fig. 5C, n=8). Animals were bled on a pre-determined sched-
ule via saphenous vein puncture. Circulating ALCAM levels were detected by 
ELISA and a comparison to pre-grafting baseline levels allowed for the detection 
of any increase in host (mouse) ALCAM and the appearance of tumor (human) 
ALCAM in response to an increasing tumor burden. Tumor-derived ALCAM levels 
showed significant weekly  increases in the serum of tumor-bearing mice (Fig. 
5B,C, and Fig. 7; P < 0.0001). Regression analysis showed a direct linear rela-
tionship  between circulating levels of tumor-derived ALCAM and tumor burden for 
35
subcutaneous xenografts (Fig. 5B; tumor-derived R2 = 0.707, p<0.0001, n = 4) 
and orthotopic xenografts (Fig. 5C; tumor-derived R2 = 0.7066, p<0.0001, n = 4). 
Figure 5: ALCAM shedding correlates with tumor burden. Circulating AL-
CAM levels were monitored longitudinally in mice bearing subcutaneously 
(S.Q.) or orthotopically  implanted PC3 cells. (A) Schematic representation of in 
vivo strategy for S.Q. and orthotopic tumor models. B and C)  Circulating levels 
of soluble host and tumor-derived ALCAM detectable in mice bearing subcuta-
neous injected PC3 cells (B)  or PC3 cells orthotopically implanted into the pros-
tate (C). Levels of ALCAM are shown as a function of time (top) or tumor burden 
at the time of experiment completion (bottom). Each point reflects mean of du-
plicate measurements ±  SD. Each line and corresponding R2 represents a best 
fit linear regression analysis. 
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Figure 6. ALCAM serum half-life in mice. Pooled serum from ALCAM WT 
mice was delivered retro-orbitally  into ALCAM KO mice (n=10) Circulating levels 
of mouse ALCAM were measured 10mins, 2, 4, 24 and 48hrs post injection. 
Baseline pre-bleed was used as negative control. ALCAM WT serum was used 
as ELISA control. 
37

	
1 10 100 1000 10000
0
200
400
600
800
Time (min)
AL
C
AM
 (p
g/
m
L)
Figure 7. Immune response modulation does not affect serum ALCAM A) 
Tumor-derived (human) ALCAM serum levels in individual mice plotted longitudi-
nally  B)  Serum levels of mouse ALCAM pre-and post-treatment with Lipopoly-
saccharide (LPS). Data are mean ±  SEM (n=5); *p<0.05 (One-way ANOVA; 
Mann-Whitney test). C) Serum levels of mouse ALCAM in pre-and post full thick-
ness skin punch. Data are mean ±  SEM (n=6); *p<0.05 (One-way ANOVA; 
Mann-Whitney test).
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In contrast to tumor-derived ALCAM, changes in host-derived ALCAM did not 
correspond to tumor burden (Fig. 5B; host-derived R2 = 0.03671, n = 4 animals; 
Fig. 5C; host-derived R2 = 0.01358, n = 4 animals). 
ALCAM shedding is mediated by ADAM17 in vitro and in vivo. Since ALCAM 
is a proteolytic target of ADAM17 we hypothesized that ADAM17 was responsible 
for TGFβ-induced cleavage of ALCAM. This hypothesis was supported by pub-
lished work demonstrating that TGFβ can increase ADAM17 activity by phospho-
rylation of the protease (136,137). Indeed, knockdown of ADAM17 using small 
interfering RNA (siRNA) transfection resulted in a loss of TGFβ-induced ALCAM 
shedding (Fig. 8A). Similar results were obtained using an ADAM17-specific in-
hibitor (Fig. 8B, Compound-32, Bristol Meyers-Squibb) (138). These studies were 
extended to orthotopic models to confirm that ADAM17 was also the primary pro-
tease responsible for ALCAM shedding in vivo (Fig. 8C). In vivo inhibitor dosing 
and efficacy was confirmed using serum TNF-alpha (Fig. 9, n=6) which demon-
strated that 50% inhibition of ADAM17 could be achieved for the duration of the 
ALCAM serum half-life (Fig. 6; 17hr) without signs of distress or toxicity. Mice 
were treated twice-daily  for 3 days with 20mg/kg of the ADAM17 inhibitor 
(Compound-32 or vehicle DMSO control). Pre-surgery, weekly, pre- and post-
treatment saphenous vein bleeds were collected. We found that inhibition of AD-
AM17 resulted in a significant decrease in serum levels of shed ALCAM ap-
proximating the 50% inhibition we achieved with our dosing studies (Fig. 9). 
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Figure 8. Ectodomain shedding of ALCAM is mediated by ADAM17 in vitro 
and in vivo.  (A) Western blot analysis of shed ALCAM in the conditioned media 
and ADAM17 in the total cell lysate of PC3 transiently transfected with either 
scrambled siRNA or siRNA targeting ADAM17. (B) Western blot analysis of shed 
ALCAM in PC3 cells treated with an ADAM17-specific inhibitor (Compound-32, 
BMS), broad-spectrum MMP inhibitor (GM6001), or diluent control. (C) Serum 
levels of tumor-derived ALCAM in 10wk old SCID mice bearing PC3-luc tumors 
and treated with DMSO diluent or Compound-32 for three days, p=0.0005
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Figure 9. Compound-32/ADAM17 inhibitor dosing in vivo. 20mg/kg of 
Compound-32 (ADAM17 Inhibitor) was delivered intraperitoneally  in WT C57/Bl6 
(n=6) mice.  Serum was collected at 6, 18 and 22hrs following one hour post-
LPS injection. ELISA was used to determine serum TNF-α levels. Serum from 
pre-bleed prior to LPS injection was used as baseline. 
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Taken together these data suggest that ALCAM cell surface shedding is medi-
ated by ADAM17 and promoted by TGFβ.
Knockdown of ALCAM in PC3 cells inhibits TGFβ-induced migration and in 
vivo dissemination to bone. Given TGFβ is a central driver of tumor cell motility 
and metastasis, we sought to determine the effects of exogenous TGFβ  on pros-
tate cancer cells in vitro. To test whether ALCAM is functionally  involved in tumor 
cell migration and metastasis, we knocked down expression in PC3-Luc cells us-
ing viral delivery of short hairpin RNA (shRNA). Three separate stable ALCAM 
knockdowns were produced (ALCAM KD 1, 2 and 3). Transduced cells were se-
lected with puromycin and subsequently subjected to flow-sorting to isolate the 
highest knockdown population (Fig. 10A). We pre-treated PC3-luc-ALCAMKD1 
cells and PC3-luc-ALCAM shControl cells with 10μg/ml TGFβ for 16hrs in serum-
free conditions, followed by initiation of MAtS assay (Fig. 10B) or scratch assay 
(data not shown). We compared both TGFβ pre-treatment and treatment at the 
time of scratch and noted similar results. The analysis revealed a loss of TGFβ-
induced migration in PC3-luc-ALCAMKD1 cells (Fig 10B). Similar observations 
were made in ALCAMKD2 and ALCAMKD3 cells. Interestingly, the reduction in AL-
CAM expression led to a slight increase in migration, possibly  due to a loss of 
ALCAM-ALCAM homotypic interaction on adjacent cells. 
 Given the critical importance of cancer cell migration in malignant tumor 
expansion and metastasis, we subsequently evaluated the contribution of AL-
CAM to primary tumor growth and bone metastasis. Primary tumor growth was 
42
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accomplished using an orthotopic model based on implantation of tumor cells 
into the anterior prostate of SCID mice (Fig. 10C, n=8 for PC3-luc-Control and 
PC3-luc-ALCAMKD1). Skeletal metastasis was accomplished by intracardiac in-
jection of tumor cells in nude mice (Fig. 10D, n=31 for PC3-luc-Control and n=25 
for PC3-luc-ALCAMKD1). Bioluminescent imaging was used to monitor tumor bur-
den for both models at weekly intervals. Interestingly, reduced ALCAM expres-
sion did not limit tumor growth within the prostate (Fig. 10C). Whole body and ex 
vivo bioluminescent imaging of the orthotopic model upon experiment completion 
confirmed that both the PC3-luc-Control and PC3-luc-ALCAMKD1 exhibited similar 
tumor burden based on luciferase activity (Fig. 10C), and comparable tumor size 
based on weight (Fig. 10D). Local invasion and mesenteric dissemination is 
common in this model (139) and was not altered by reduced ALCAM expression. 
 In contrast to the orthotopic model, a reduction in ALCAM resulted in a 
significant decrease in skeletal metastasis (Fig. 10E). Both incidence and meta-
static burden were reduced. Approximately 75% of mice injected with PC3-luc-
Control tumor cells developed bone metastasis while only 17% of the mice in-
jected with PC3-luc-ALCAMKD1 cells developed bone lesion. In addition, mice that 
did develop  skeletal metastases formed by  PC3-luc-ALCAMKD1, the number of 
lesions per mouse was greatly reduced (0.2 events versus 1.4 events , Fig. 10F). 
The orthotopic and intracardiac experiments were repeated with PC3-luc-
ALCAMKD3 and similar results obtained. 
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ALCAM expression contributes to tumor cell survival in the bone microen-
vironment. To determine the biologic importance of tumor-derived ALCAM in 
prostate tumor growth in the bone, PC3-luc-Control (n=8), PC3-luc-ALCAMKD2 
(n=8) and PC3-luc-ALCAMKD3 (n=8) were injected into the tibia of nude mice. Fol-
lowing intratibial injection, luminescent and X-ray imaging was used to monitor 
tumor burden over time (Fig. 11A). Quantitation of the bioluminescent signal 
showed a markedly lower growth rate for the ALCAM KD cells (Fig 11B). At com-
pletion of the experiment 100% of control mice exhibited lesion compared to an 
80% incidence in limbs bearing PC3-luc-ALCAMKD3 tumor cells (Fig. 11C). AL-
CAMKD intratibial tumors continued to exhibit reduced ALCAM expression (Fig. 
11D). Detailed imaging of the osteolytic lesions by microCT (Fig. 12A) further 
confirmed decreased lesion area and increased bone volume in the bones con-
taining ALCAM KD cells (Fig. 12B and C). Finally, the histological visualization of 
bone tumors generated by control and ALCAM KD cells resulted in reduced bone 
tumor size upon ALCAM knockdown (Fig. 12D). Tibias in the PC3-luc-vector, 
PC3-luc-ALCAMKD2 and PC3-luc-ALCAMKD3 were stained for the osteoclast 
marker, tartrate-resistant alkaline phosphatase (Fig. 13). Both the ALCAM KD 
tumors induced osteolytic lesions as evidenced by osteoclast presence adjacent 
to tumor lesions suggesting that the ability  to induce bone-remodeling was not 
deficient in these cells.
 We then carried out immunofluorescent staining for cleaved caspase-3 
(Fig. 12E, apoptosis) and Ki67 (Fig. 12F, proliferation) on intratibial bone tumors 
harvested at 28 days post injection  Compared to the control tumors, the bone 
45
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Figure 12: Tumor-derived ALCAM impacts tumor survival and proliferation 
in the bone microenvironment of intratibial bone tumor model. A) Repre-
sentative three dimensional reconstitutions of microCT images from mice in-
jected with PC3-luc-vector, PC3-luc-KD1 and PC3-luc-KD2 tumor cells B) Box-
plots of average BV/TV (bone volume/total volume) by group for the PC3-luc-
vector, PC3-luc-KD2 and PC3-luc-KD3 tumor bearing mice. Data represents 
quartiles with dots indicating outliers (1.5x upper or lower quartile; n=16 tibias/
group) *p<0.05, **p<0.01, (One-way ANOVA p=0.0047. Post-hoc Mann-Whitney) 
C)  A  boxplot representing the lesion area calculated from end-point x-ray images 
from the same experiment shows dramatic decrease in the lesion area in the 
KD2 and KD3 tumor lesions compared to vector control (One-way ANOVA 
p=0.0003. Post-hoc Mann-Whitney **p<0.01, ***p<0.0001. n=8/group). Lesion 
areas were measured using arbitrary pixel unit. D) Representative H&E stains of 
osteolytic bone lesions in the hind leg of mice. Outlines indicate the osteolytic 
tumor lesion within the bone. E) Representative immunofluorescent staining of 
cleaved caspase-3 positive cells (red) in tibias of PC3-luc-vector, PC3-luc-KD2 
and PC3-luc-KD3 tumor-bearing mice. F)  Representative immunofluorescent 
staining of Ki67 proliferating cells (red) in tibias of PC3-luc-vector, PC3-luc-KD2 
and PC3-luc-KD3 tumor-bearing mice. Data are mean ± SEM (n=8/group); 
*p<0.05, **p<0.01, ***p<0.005 (One-way ANOVA; Mann-Whitney test). G)  Apop-
tosis in the tumor-bone microenvironment as a function of total cell number was 
assessed by staining for cleaved caspase-3 in PC3-luc-vector, PC3-luc-KD2 and 
PC3-luc-KD3 tumor bearing tibias of mice 4 weeks post-injection. H)  Proliferation 
in the tumor-bone microenvironment as a function of total cell number was as-
sessed by staining for Ki67 in PC3-luc-vector, PC3-luc-KD2 and PC3-luc-KD3 
tumor bearing tibias of mice 4 weeks post-injection.
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Figure 13. Tumor-induced osteolysis not affected by decreased ALCAM 
expression. Representative TRAP stained photomicrographs of PC3 shControl 
and shALCAM injected animals at day 28.
tumors created by both ALCAM KD cells exhibited elevated levels of cleaved 
caspase-3 suggesting that these cells are experiencing a reduced ability  to sur-
vive (Fig. 12G). In addition, bone tumors from PC3-luc-ALCAMKD3 had signifi-
cantly lower Ki67 staining suggesting that ALCAM contributes to both prolifera-
tion and survival (Fig. 12H). 
DISCUSSION
We have established for the first time that ALCAM plays a role in prostate cancer 
establishment in the bone microenvironment. ALCAM mRNA is elevated in ma-
lignant disease yet by immunohistochemistry  it is frequently absent from the tu-
mor cell surface in advanced disease (Fig. 2D) (80,99,122). We have demon-
strated recently that in colorectal cancer tissue, ectodomain shedding is respon-
sible for the apparent loss of ALCAM immunohistochemical detection (113). This 
shedding is likely the cause for conflicting results reported for several malignan-
cies (95). Indeed the protease responsible for shedding of ALCAM ectodomain, 
ADAM17, is elevated in advanced prostate cancer (Fig. 2B) (140). These data 
implies that while ALCAM gene transcription is elevated in prostate cancer, ecto-
domain shedding depletes the cell surface of intact protein in advanced disease. 
Regression analysis showed a direct linear relationship  between circulating lev-
els of (human) tumor-derived ALCAM and tumor burden in animals with subcuta-
neous xenografts (Fig. 5B) and orthotopic xenografts (Fig. 5C). In contrast, the 
host-derived ALCAM did not correspond to tumor burden (Fig. 5B&C;), demon-
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strating that elevations in circulating ALCAM are tumor-specific. Consistent with 
this observation, host-derived ALCAM does not increase, but rather decreases 
slightly, in immunocompetent mice challenged with LPS (a model of acute in-
flammation) or full-thickness skin punch (a model for wound-healing,Fig. 7B&C, 
respectively). These data suggest that tumor-derived ALCAM is a marker specific 
of tumor burden and that host ALCAM is not significantly shed in response to the 
tumor burden. 
 The TGFβ responsiveness of ALCAM (Fig. 4) together with the elevated 
levels of ALCAM expression and shedding observed in cancer patients (Fig. 2) 
(90,103,113) and experimental models (Fig. 4 &5) suggested that ALCAM could 
contribute to the metastatic behavior of prostate cancer cells. In vitro suppression 
of ALCAM expression by  stable transfection of ALCAM targeting shRNAs signifi-
cantly inhibits prostate cancer cell migration in vitro in response to exogenous 
TGFβ. This pleiotropic cytokine is particularly important in establishing the vicious 
cycle of tumor cells in the bone microenvironment (116) and is known to be ele-
vated in the plasma of patients with breast and prostate bone metastasis (141). 
These observations demonstrate that ALCAM contributes to TGFβ-induced mi-
gration and skeletal metastasis, but does not influence primary tumor growth or 
local invasion. 
 The mechanism by which ALCAM participates in metastasis of prostate 
cancer to bone remains unclear. Recent data have shown that activation of NF-
κB in prostate cancer cells increases RANKL and PTHrP. NF-κB proteins are an 
important class of transcriptional regulators in prostate cancer. Similar to inactiva-
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tion of NF-κB signaling in prostate cancer cells, our data show decreased ex-
pression of ALCAM, a downstream target of the p65/p55 subunit of NF-κB, inhib-
its tumor establishment and growth in the bone microenvironment (142,143). 
Both the over-expression of ALCAM and nuclear p65 NF-κB in prostate cancer 
cells correlates with chemoresistance, advanced stage, PSA recurrence and 
metastatic spread (99,107,144-147). While we did not observe a reduction in os-
teoclast activity by  TRAP staining (Fig. 13) in ALCAM knockdown bone meta-
static sites, one would suggest NF-κB exerts additional pro-metastatic function 
through modulation of ALCAM expression, independent of increasing osteoclas-
togenesis. Intratibial tumor formation was enhanced in LNCaP cells expressing 
constituitively activated NF-κB through retroviral infection with a mutant IKK2 
(142). If indeed NF-κB activation increases ALCAM expression, it is possible that 
ALCAM expression and ectodomain shedding can have specific, yet separate 
roles in tumor cell growth versus tumor establishment. This provides a rationale 
for further investigation into the role of ALCAM in prostate bone metastasis.
 Within the metastatic cascade there are many sequential steps that can 
contribute to the overall success of any single metastatic lesion. Evaluation of 
primary tumor growth and experimental metastasis suggest that, in our model of 
prostate cancer, ALCAM contributes to skeletal colonization after arrival to the 
secondary site. Close examination of metastatic colonies from mice injected in-
tracardially with PC3-luc-ALCAMKD1 and PC3-luc-ALCAMKD3 revealed a reduced 
lesion size, suggesting that ALCAM might be important for tumor growth in bone. 
Intratibial bone tumors composed of ALCAM knockdown cells remained small 
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throughout the duration of the experiment suggesting that there was not a lag in 
tumor growth but rather a persistent reduced ability  to proliferate or, conversely, a 
decreased ability to survive. 
 Although there was no evidence of reduced proliferation in vitro (FIg. 14), 
the in vivo data suggest that tumor-derived ALCAM is important for growth of tu-
mor cells in the bone. Intriguingly, PC3-luc-ALCAMKD2, which retains more AL-
CAM expression than PC3-luc-ALCAMKD3 (Fig. 11A), did not exhibit reduced pro-
liferation suggesting that the threshold of ALCAM expression that influences cell 
survival is different from the threshold influencing cell proliferation. These data 
demonstrate for the first time that tumor-derived ALCAM impacts tumor growth 
and expansion in the bone microenvironment by promoting cell proliferation and 
survival. Our results show that ALCAM expression in the bone microenvironment 
can have a significant impact on tumor cell survival. This is in accordance with in 
vitro data whereby ALCAM gene silencing in MCF-7 tumor cells resulted in in-
creased cleaved caspase-7 and PARP, in addition to decreased levels of the 
apoptosis regulator, Bcl-2 (148). Taken together, these observations suggest a 
protective , anti-apoptotic role of ALCAM in tumor cell survival in the bone mi-
cronenvironment. Extravasation of tumor cells is considered an important step in 
metastasis because tumor cells must adhere and transverse the endothelial layer 
before settling at a secondary site (149). Both soluble ALCAM-Fc and blocking 
ALCAM antibodies are able to decrease in vitro transendothelial migration of 
THP1 monocytes suggesting this may be a requirement for transendothelial mi-
gration of tumor cells (150). In our study, intracardiac injection of prostate cancer 
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Figure 14. Effect of ALCAM knockdown on in vitro proliferation. Graph rep-
resents tumor cell proliferation over time as assessed by total cell counts over 
72 hours.
cells with reduced ALCAM expression resulted in a dramatic reduction of tumor 
incidence (Fig. 10E). On the contrary, intratibial injection did not significantly im-
pact tumor incidence (Fig. 11C), rather survival (Fig. 12F), suggesting a dual ad-
hesive and signaling function of ALCAM whereby the intracellular signaling func-
tion of ALCAM functions to serve a protective role in apoptosis, and the extracel-
lular adhesive function is required for extravasation and subsequent colonization 
at a secondary site. While we have convincing data that ALCAM expression is 
important in the osteotropism and survival of tumor cells in the bone, (Figure 10 
& 12, respectively) further work is necessary to fully elucidate the mechanisms 
involved.
 Here we have presented evidence that ALCAM not only serves as a longi-
tudinal molecular indicator of tumor burden, but functionally contributes to metas-
tasis to bone. Clinically, ALCAM may be a surrogate marker for bone metastasis 
in prostate cancer patients. In support of the hypothesis that ALCAM is required 
for tumor cell maintenance in the bone microenvironment, we show that a reduc-
tion in ALCAM expression reduces cell survival in the bone microenvironment. 
The relevance of ALCAM in the bone microenvironment is coupled with our data 
showing ALCAM expression is driven by TGFβ, a known contributor of the vi-
cious cycle in bone metastasis (151). Dissecting the molecular mechanisms that 
contribute to tumor cell survival and growth in the bone is critical for the devel-
opment of targeted therapies and clinical biomarkers of disease progression. Fur-
ther elucidation of the role of ALCAM in the bone micronenvironment and clinical 
application ALCAM as a candidate marker of bone metastasisis  is warranted and 
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could impact detection and treatment intervention in prostate bone metastatic 
disease.
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CHAPTER I I I
ELEVATED ALCAM SHEDDING IN COLORECTAL CANCER COR-
RELATES WITH POOR PATIENT OUTCOME
INTRODUCTION
Colorectal cancer (CRC) is the third most frequently diagnosed cancer, and sec-
ond leading cause of cancer-related deaths in the US (152). Current prognosis 
for CRC patients predominantly rely on pathologic UICC/AJCC tumor node me-
tastasis (TNM) staging classification (153). Although TNM staging successfully 
stratifies high-risk patients, there is significant variability in the rate of disease 
progression within each stage. Particular concern exists for early stage disease 
(Stage I and II) where patients can progress more rapidly  than expected. It is well 
known that approximately 30% of stage II CRC patients die of recurrent and 
metastatic disease. Identification of patients at risk of recurrence/progression 
could inform clinicians on adjuvant chemotherapeutic treatment decisions. Bio-
markers can assist in identifying those patients that require more aggressive in-
tervention or patients at risk of relapse after initial treatment. Promising clinical 
tests including Oncotype DX™ and Coloprint™ evaluate possible disease pro-
gression by assessing gene expression. These tests are not yet widely  applied, 
possibly because their epigenetic evaluation reflects gene expression which does 
not always reliably predict actual cellular behavior. Thus, existing prognostic tests 
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would be enhanced with the addition of biomarkers that report on cancer prog-
nostication.
 While clinical trials have demonstrated less than 5% 5-year survival benefit 
from adjuvant therapy for unselected stage II colon cancer patients (154), it is 
clear that a subset of these patients are at high risk for poor outcome and would 
likely  benefit from adjuvant therapy  (155,156). Those high-risk stage II patients 
have similar outcomes to patients with stage III tumor status (157), highlighting 
the need for molecular stratification parameters to identify high-risk patients with 
apparent early stage disease. Attempts made to stratify patients using gene ex-
pression profiles have experienced some success but have not been translated 
to the clinic (158,159). Molecular indicators capable of identifying subgroups of 
patients with poor prognosis and therapeutic benefit include microsatellite insta-
bility and 18q loss of heterozygosity  (LOH), however, 18qLOH has not been 
translated to a useful predictive tool for clinical use (160). 
 ALCAM has been highlighted as a putative biomarker for the progression of 
many cancers, including CRC (81,90,109,110,112,161,162). ALCAM is a cell-cell 
adhesion protein that has been identified in a broad array of biological processes 
including inflammatory responses, neuronal outgrowth and epithelial migration 
(120). Unlike most candidate biomarkers, ALCAM expression is not tissue-
restricted and it is commonly found in most epithelia and related carcinomas and 
contributes to tumor progression by controlling migration. Its molecular activity 
appears to be regulated through shedding of the extracellular domain. Conse-
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quently, advanced disease tissues continue to express ALCAM but exhibit an 
elevated level of ALCAM shedding. 
 ALCAM has been evaluated for CRC  in five published reports.  Unfortu-
nately, the findings from these studies are contradictory (20,52,53,109,162). In a 
study characterizing the expression of ALCAM in the gastrointestinal tract and 
colorectal cancer, ALCAM was found to be highly expressed in the colon crypts 
of normal tissue and heterogeneously expressed in tumor sections (53). In a 
study of 299 CRC patients, membranous ALCAM expression was a positive 
prognostic indicator for overall survival (109). Similarly, a previous study by Lugli 
et al. also found the loss of membranous ALCAM to be indicative of worse patient 
prognosis (162). In contrast, Weichert et al. reported that membranous ALCAM 
expression is associated with decreased patient survival (20). A subsequent 
study by Horst et al (52) found ALCAM not to be correlated with CRC  patient out-
come.  
 Although these studies are contradictory, ALCAM has significant potential 
as a biomarker for CRC because it is not only readily detected in CRC but is also 
functionally and clinically associated with a large number of cancers including: 
colorectal (20,52,109,162), prostate (80,99), breast (100,112), gastric (105), thy-
roid (90), pancreatic (103), melanoma (94), and ovarian (81).  At the clinical level, 
shed ALCAM is detectable in the serum of breast, thyroid, ovarian and pancreatic 
cancer patients, and the loss of cell surface ALCAM is associated with poor 
prognosis (90,107,112,163). These data suggest that the proteolytic cleavage of 
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ALCAM is functionally  important in tumorigenesis, and detection of ALCAM 
shedding may function as a prognostic biomarker.
 In this study, we sought to determine if ALCAM shedding in human primary 
colorectal cancers reflects a unique molecular progression of the tumor and con-
sequently acts as a prognostic biomarker. For this purpose we developed a 
unique dual stain to detect both the extracellular and the intracellular domain of 
ALCAM within the same tissue. We find that ALCAM shedding in the primary tu-
mor correlates strongly  with a poor clinical outcome. This was particularly striking 
in stage II patients in which disease-specific survival was significantly  worse 
when the tumor tissue exhibited high ALCAM shedding.
MATERIALS AND METHODS
Cell lines and mice. The continuous cell lines for cancer of the breast (MDA-
MB-231 and MCF-7), prostate (PC3 and Du145) and colon (RKO, DLD, LOVO, 
LS174t, HCT116, HCA7, Scko1, Caco2, HT29, KM12c and KM12) were cultured 
in their appropriate basal media (DMEM or RPMI) with 10% FBS to confluence 
before lysis with 1% Triton-X 100 in PBS. ALCAM knockout mice (c57bl/6 AL-
CAM-/-) were purchased from Jackson Laboratories. Mouse tissues were surgi-
cally resected, snap frozen and subsequently extracted with 1% Triton-X 100 ly-
sis buffer. 
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Western Blot Analysis. SDS–PAGE under non-reducing conditions and transfer 
of proteins to a PVDF membrane has been described previously. After blocking 
with 5% skimmed milk in PBS/0.05% Tween-20, blots were probed with primary 
antibodies for extracellular ALCAM (Clone 105902; R&D Systems) and selected 
hybridoma clones, followed by peroxidase-conjugated secondary antibody and 
ECL (Perkin-Elmer) detection.
Lentivirus-delivered RNA Interference. Four individual constructs containing 
shRNAs for human ALCAM and a negative control (scrambled sequence) were 
purchased from Sigma (Mission shRNA). Constructs were packaged for viral 
production and infection and tested for target knockdown. For viral packaging, 
constructs were co-transfected into 293T cells using Fugene HD (Roche Applied 
Science). Media containing viruses were collected 48hr after transfection. PC3 
cells were infected with the viruses in the presence of Polybrene (8μg/ml) for 
24hr and then subjected to selection by 5μg/ml puromycin. Two constructs with 
≥90% knockdown efficiency  as determined by immunoblotting and flow cytometry 
were used for further studies.
Human material. The protocols and procedures for this study were approved by 
the institutional review boards at the University of Alabama-Birmingham Medical 
Center, Vanderbilt Medical Center (VMC), the Veterans Administration Hospital 
(Nashville, TN), and the H. Lee Moffitt Cancer Center (MCC; Tampa, FL). Tissue 
specimens from 250 colorectal cancer patient enrolled at Vanderbilt Medical Cen-
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ter (VMC, n = 55) and Moffitt Cancer Center (MCC, n = 195) were used for gene-
expression microarray  analyses as described previously (159). All patients had a 
diagnosis of colorectal adenocarcinoma. Each cancer specimen was staged ac-
cording to American Joint Commission on Cancer (AJCC) guidelines (stages I-
IV), and 10 normal adjacent specimens were deemed to contain only  normal 
colonic tissue by a certified gastro-intestinal pathologist. VMC 55 includes 14 pa-
tients from the University of Alabama-Birmingham Medical Center (159). Microar-
ray data for the NCI cell lines was obtained through the NCBI Gene Expression 
Omnibus (GEO data set GDS1761).
 A tissue microarray containing 75 primary colorectal carcinomas and 12 
normal age and sex-matched colorectal mucosa was constructed using 2mm 
cores in triplicate. Specimens from 69 CRC patients  and 12 normal colonic mu-
cosa were suitable to be used in the dual staining analysis.  Subsequent expan-
sion of this dataset was accomplished by selection of 36 stage II patients under 
IRB #120063 providing analysis for a total of 105 CRC and 12 normal mucosa 
with triplicate representation of each patient. Collection of serum from control 
(n=6), non-cancer patients (n=48) and colorectal patients immediately  before 
surgery (pre-op, n=71) or after treatment (followup, n=20) at was accomplished 
at Vanderbilt Medical Center under IRB# 121365.
ALCAM Dual Immunofluorescence stain. Immunofluorescent staining for AL-
CAM in tissues was performed with hybridoma HPA010926 (Sigma Prestige An-
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tibodies) directed against the extracellular domain and clone 1G3A1 (obtained 
from our fusion) directed against the intracellular domain (Table 3).  Sections cut 
from patient tissue and tissue microarrays were deparaffinized in xylene and re-
hydrated. Sections were blocked in 20% Aqua Block™ after pressure cooker an-
tigen retrieval in citrate buffer (pH 6.0) . Samples were immunostained with 
mouse monoclonal intracellular ALCAM antibody, 1G3A1, (3μg/ml) and rabbit 
monoclonal extracellular ALCAM antibody, HPA010926 (1:250 dilution). The ar-
rays were incubated with Alexa-546 Goat anti-rabbit (1:500) and Alexa-647 Goat 
anti-mouse secondary antibody (1:500, LifeTechnologies). The sections were 
counterstained with 2μg/ml of Hoechst for 2mins, and mounted with Prolong® 
Gold Anti-fade.
  
Image acquisition and quantitative analysis of ALCAM shedding. Tissue mi-
croarrays were imaged using the Ariol® SL-50 platform from Genetix. Image 
analysis and quantitation were performed using the open-source software Im-
ageJ (FIJI). The analysis pipeline was designed as follows: a) The tumor area 
was selected using the free-hand selection tool. b) The color image was split into 
its red, green and blue component channels. c) Image thresholding was used to 
generate the detectable region of intracellular ALCAM staining (red channel) and 
extracellular ALCAM staining (green channel). d) Intact ALCAM was determined 
as the area of co-localized intracellular and extracellular ALCAM (red and green 
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ALCAM
Antibody reactivity
Status Intracellular 
Domain (1G3A1)
Extracellular Domain 
(HPA10926)
Intact ALCAM + +
ALCAM Shedding + -
ALCAM Absent - -
1G3A1HPA10926
ALCAM Schematic
Table 3. Depiction of ALCAM immunoreactivity  for HPA10926 which reacts with 
the extracellular domain and 1G3A1 which is specific for the intracellular domain
channel) while ALCAM shedding was determined as the area of intracellular AL-
CAM that lacks extracellular ALCAM (red but no green). The sum of these two 
represents total ALCAM expression.
Immunization and Fusion. Four A/J mice were immunized with the ALCAM C-
terminal peptide sequence CKDLGNMEENKKLEENNHK (New England Peptide) 
based on the cytoplasmic sequence of ALCAM (Fig. 15). The peptide was conju-
gated to Keyhole Limpet Hemocyanin (KLH) using the N-terminal cysteine. Initial 
immunization was performed with 50 μg of purified antigen emulsified in 50% 
phosphate-buffered saline (PBS), 50% Freund’s complete adjuvant (Pacific Im-
munology) injected subcutaneously into the nape of the neck (50%) and intra-
muscularly to the gluteal muscles (50%). Subsequent boosts were performed 
subcutaneously with incomplete Freund’s adjuvant. Serum collected post injec-
tion was assayed for reactivity with the antigen by enzyme-linked immunoadsor-
bent assay (ELISA) and western blot analysis. The mouse with the highest titre 
was chosen for the final intraperitoneal boost followed four days later by electro-
fusion of spleen-derived cells by standard methods with SP2/0 myeloma cells. 
Fused cells were plated for under selection in semi-solid media and antigen-
reactive colonies identified by  solid phase ELISA were picked using a ClonePix 
robotic system (Genetix, Ltd.). ALCAM-specific antibodies were initially identified 
by direct ELISA using the immunogen, and subsequently verified by western blot 
analysis and immunofluorescence using intact ALCAM. Selected clones were 
scaled up and inoculated into one liter bioreactors (Wilson Wolf Manufacturing 
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Figure 15. Multi-species sequence alignment was carried our using the Ge-
neious™ bioinformatics software. Along the top  of each alignment is the se-
quence identity plot comparing the sequence across species. Green peaks are 
100% identity  among species; yellow and red are lower identities. Immunogen 
sequence is located in the cytoplasmic tail consisting of a highly conserved 14 
amino acid sequence.
Corporation) and grown for 3-4 weeks. Purified antibodies were obtained by af-
finity chromatography on Protein-G sepharose (GE Life Sciences) from 
bioreactor-generated supernatants.
Enzyme-linked Immunosorbent Assay.(Direct ELISA). Flat-bottomed 96-well 
microtiter plates were coated with KLH-conjugated peptide at 10 μg/ml in 
Carbonate-Bicarbonate buffer pH 9.6 (15mM Na2CO3, 30mM NaHCO3, 0.001% 
Thimerosal) for 4hr (37°C) or overnight (4°C). Coated plates were washed and 
blocked with 1% BSA in PBST (PBS + 0.1% Tween-20) using an ELx405 Select 
(Bio-Tek). Supernatant or diluted sera (100μl) was allowed to incubate at 37°C 
for 1hr before washing three times with PBST. Peroxidase-conjugated goat anti-
mouse IgG Fc fragment specific secondary antibody (Jackson Immunoresearch 
Labs) diluted 1:5000 in PBST/1% BSA was added to the wells and incubated 1 hr 
at 37°C. Plates were washed three times in PBST and bound antibodies were 
detected utilizing the colorimetric substrate ABTS (Sigma) and hydrogen perox-
ide according to vendor instructions). For whole-cell lysate ELISA, flat-bottomed 
high-binding 96-well plates were coated with 10μg of whole protein lysate in PBS 
and incubated overnight at room temperature. Coated plates were subsequently 
treated as described above for KLH-conjugated peptide. 
(Sandwich ELISA). For the detection of human ALCAM in serum samples from 
colorectal cancer patients, 96-well microtiter plates (Costar 9018) were coated 
with 2 μg/ml of capturing antibody overnight at 4°C. Human serum samples were 
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diluted 1:80 in PBS/1%BSA and the ELISA reaction was performed as described 
by manufacturer protocol (R&D Systems).
Statistical analysis. Descriptive statistics were applied to show patient's basic charac-
teristics stratified by ALCAM shedding score. Wilcoxon rank sum test and Kruskal-Wallis 
test were applied to exam the mRNA expression difference between normal tissues and 
cancer tissues or the ALCAM shedding percentage among normal patients and cancer 
patients in all different stages. Kaplan-Meier curve was used to estimate the survival 
probability for each group, with corresponding p-value and hazard ratio calculated from 
log-rank test. Receiver Operating Characteristic (ROC) curves were used to identify the 
optimal specificity and sensitivity for patient stratification. For survival analysis the pa-
tient population was dichotomized across a value of ALCAM shedding or intact ALCAM 
as defined by the ROC curves. For ALCAM shedding this was 0.75 and for intact ALCAM 
this was 0.15 For shedding the p-values of all statistical tests were two-sided and con-
sidered significant when p<0.05 where * denotes p< 0.05, ** denotes p< 0.01 and *** 
denotes p< 0.001. All statistics were completed using either R, SPSS or GraphPad 
Prism. Multivariable analysis analysis using logistic regression was performed on stage 
II patients (n=66; median follow-up, 70 months; median age of diagnosis, 67 years). The 
variables included were ALCAM shedding, age at time of diagnosis, race and gender 
with an incidence of 51.5% (34 events) for overall survival and 26.9% (18 events) for 
disease specific survival.
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RESULTS
Correlation of ALCAM and ADAM17 expression with survival of colorectal 
cancer patients. In normal colorectal tissue, immunohistochemical staining for 
the extracellular domain of ALCAM using HPA10926 reveals the protein at areas 
of cell-cell contact within the epithelial cells of the colonic crypts and in hemo-
poietic cell populations of the stroma (Fig. 16A i and ii).  In contrast to normal co-
lon, the concomitant staining of colorectal cancer tissue reveals a very heteroge-
neous staining. Within the same tumor, some regions exhibit elevated ALCAM 
(Fig. 16A iii) while others exhibit irregular staining (iv) or lack ALCAM staining all-
together (v). Similar heterogeneity of ALCAM staining is observed in a publicly 
available tissue microarray (proteinatlas.org) (134)). ALCAM protein expression 
is detectable in 12/14 CRC cell lines (Fig. 16B and Fig. 17). Expression of the 
ALCAM mRNA in CRC cell lines among the NCI60 (Col) is intermediate between 
the low expressing leukemia (Leu) cell lines and the high expressing breast can-
cer (Br) cell lines (Fig. 16B). 
 To evaluate ALCAM mRNA expression in colorectal cancer, a single cohort 
consisting of 250 patients obtained through a multi-institutional collection(VUMC, 
UAMC and Moffitt Cancer Center) was analyzed. ALCAM mRNA is elevated in 
cancer patients (Fig. 16C, p<0.001) and univariate analysis revealed that high 
ALCAM expression was in fact associated with significantly decreased survival 
(Fig. 1C, p<0.0001). Similarly, expression of ADAM17 (the sheddase of ALCAM) 
was also significantly elevated in colorectal cancer (Fig. 16D, p<0.0001)). The 
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Figure 16. ALCAM expression in colorectal carcinoma and its correlation 
to patient outcome. A) Representative immunohistochemical staining for AL-
CAM in normal and tumor colon sections using an antibody directed to the extra-
cellular domain of ALCAM (HPA010926). B) Expression of ALCAM in CRC cell 
lines evaluated by immunoblotting (left) and microarray analysis (right, 
GDS1761). Expression (mRNA) of ALCAM (C) and ADAM17 (D) in a cohort of 
250 colorectal cancer patients was correlated to patient survival after dichoto-
mizing the population across its mean expression into patients with “High AL-
CAM” and “Low ALCAM”. E) Using an ALCAM sandwich ELISA, circulating lev-
els of shed ALCAM were evaluated in serum from cancer-free patients (n=48) 
and compared to serum from CRC patients at time of diagnosis (pre-op, n=42) 
and serum from patient at time of followup after treatment (post-op, n=19). F) 
CRC patients were stratified according to stage (I-IV) and compared to cancer-
free patients (n=48) and healthy adults (n=6). Box plots show the mean, stan-
dard deviation and full range of the expression data. Survival is presented with 
Kaplan-Meier plots and log-rank test was used to evaluate significance.
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Figure 17. ALCAM expression in continuous cancer cell lines. Lysates from 
human cancer cell lines immunoblotted for ALCAM using an antibody specific for 
its extracellular domain.
association of ADAM17 expression with patient survival was not statistically sig-
nificant (p=0.067), but its elevated expression in CRC  together with its estab-
lished ability to cleave ALCAM is sufficient to suggests that ADAM17 is available 
to cleave ALCAM and increase its shedding within the tumor microenvironment. 
Indeed, previous studies reported heterogeneous staining of ADAM17 in colorec-
tal cancer (Merchant et al., 2008), which might be responsible for the variable de-
tection of ALCAM extracellular domain within the tissue. The soluble extracellular 
domain can be detected in the serum of some cancer patients (90,112). How-
ever, ALCAM-specific ELISA of serum from CRC patients did not reveal a corre-
lation between disease progression and increase in circulating ALCAM when 
comparing serum obtained from cancer free patients and serum obtained from 
CRC patients prior to, and after therapy (Fig. 16E). Detailed comparison of can-
cer free patients and normal healthy individuals versus increasing stages of CRC 
patients revealed no significant correlation with circulating levels of ALCAM (Fig. 
16F).
 The histological detection of membranous ALCAM had been found to corre-
spond negatively  with patient survival (20). Using an antibody to the extracellular 
domain of ALCAM, a histological evaluation of a 69-patient cohort was performed 
(Fig. 18). While the presence or absence of membrane staining did not corre-
spond with overall or disease specific survival, the loss of detectable cytoplasmic 
ALCAM corresponded with very  poor prognosis. However, only 8/69 patients 
(12%; Fig. 18, bottom right) were negative for cytoplasmic ALCAM while 39/69 
(56%; Fig. 18, bottom left) lacked membranous ALCAM. This loss of ALCAM from 
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Figure 18. Lack of cytoplasmic ALCAM corresponds with poor patient out-
come. Detection of ALCAM on the membrane vs in the cytoplasm. A tissue mi-
croarray of 75 CRC and 12 normal colonic tissues was stained by traditional IHC 
for the extracellular domain of ALCAM. Membranous and cytoplasmic staining 
was stained and scored by an independent pathologist in a blinded manner.
the membrane (with concomitant retention of cytoplasmic staining) is likely  to be 
due to shedding of the ectodomain from the cell surface. 
Production and validation of an antibody specific for the cytoplasmic do-
main of ALCAM. Since ALCAM shedding occurs on the surface of the tumor 
cells, we hypothesized that shedding might be detectable within the tumor tissue 
itself. In order to achieve this, we thought to develop an ALCAM dual-stain based 
on independent detection of the intracellular and extracellular domains with 
domain-specific antibodies (Fig. 19A). Using these antibodies in histological 
staining of normal and tumor tissue sections should enable the detection of AL-
CAM shedding in situ (Table 3). To accomplish this, a unique antibody directed to 
the cytoplasmic tail of ALCAM was generated using a 14 AA sequence from the 
cytoplasmic tail (Fig. 15) conjugated to KHL to immunize four A/J mice. Spleens 
from two seropositive mice were fused and 125 viable hybridomas selected from 
>8000 antigen-reactive clones were evaluated by comparing reactivity  to native 
ALCAM and KLH using direct ELISA (Fig. 20A). ALCAM-specific hybridomas 
were validated by immunoblotting using whole cell lysate to confirm binding to 
intact ALCAM protein (Fig. 20A). Antibody  specificity for ALCAM was verified by 
comparing reactivity with lysates from control and ALCAM knockdown cells (Fig. 
20B) and mouse tissue from wild type and ALCAM-/- mice (Fig. 19B). Antigen 
specificity was confirmed by competitive blocking using the immunizing peptide 
during immunoblotting (0.1 or 1μg/ml, Fig. 20C) and histological staining (1μg/ml, 
Fig. 19C). As expected, peptide competition with the immunizing peptide resulted 
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Figure 19. The specificity of anti-ALCAM ICD confirmed by analysis of AL-
CAM in ALCAM-/- mice. A) Schematic representation of ALCAM and its organi-
zation as a cell-cell adhesion molecule. Individual domains are presented as 
ovals (extracellular IgG-like domain) or rectangles (intracellular domain). B) The 
antibody 1G3A1 specific for the cytoplasmic tail of ALCAM was used to im-
munoblot 40μg of liver extracts from wild type and ALCAM-/- mice. C) ALCAM 
specificity of individual clones was evaluated by  outcompeting antibody binding 
with the immunizing peptide in immunofluorescence staining of human lung tis-
sue sections.
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Figure 20. Screening and validation of an antibody specific to the cyto-
plasmic domain of ALCAM. A) B) Individual hybridoma clones reactive to the 
immunizing peptide were screened by direct ELISA using whole cell lysate from 
a cell line expressing high levels of ALCAM (PC3). A 1.0 OD was used to select 
clones for further validation by immunoblotting cutoff. Three high titre clones 
chosen for further validation were 1G3A1 (ii), 1G3B3 (iv), and 1G3CF (i). B) Hy-
bridoma clones 1G3A1, 1G3B3, and 1G3CF were further for specificity to AL-
CAM by comparing their reactivity  to ALCAM with a commercial antibody (di-
rected against the extracellular domain) using lysates from parental PC3 cells 
and PC3 cells with shRNA-mediated knockdown of ALCAM. C) ALCAM specific-
ity of individual clones was further evaluated by  outcompeting antibody binding 
with the immunizing peptide in Immunoblots of whole cell lysates (PC3). D) 
Specificity of purified 1G3A1 against the cytoplasmic tail of ALCAM was con-
firmed by immunoblotting intact ALCAM (whole cell lysate; Lys.) and shed AL-
CAM (conditioned medium; C.M.) from PC3 cells.
in a loss of Intracellular ALCAM. The stable hybridoma 1G3A1 was selected as 
the most promising antibody based on its reactivity  in ELISA, immunoblot, immu-
nofluorescence and standard immunohistochemistry. Specificity of 1G3A1 for the 
cytoplasmic tail of ALCAM was defined by  its ability to detect intact ALCAM in cell 
lysates but not shed ALCAM in conditioned medium (Fig. 20D). In contrast, the 
commercial antibody  against the extracellular domain of ALCAM (R&D) detects 
intact as well as shed ALCAM which lacks the cytoplasmic domain.
Dual-staining for the intracellular and extracellular domains of ALCAM in 
normal and tumor tissue. Using the antibody 1G3A1 to specifically detect the 
cytoplasmic domain of ALCAM together with the commercial antibody 
HPA010926 specific for the extracellular domain, we developed a dual-staining 
procedure for ALCAM in human tissues (Fig. 21&22). Three-color staining (Nu-
clei: blue, Extracellular Domain: green, Intracellular Domain: red) was performed 
on tissues along the digestive tract including stomach (Fig. 21A) and colon (Fig. 
21B). In normal tissues, detection of the extracellular and cytoplasmic domains of 
ALCAM coincided, thereby suggesting that ALCAM is expressed and present in 
its intact form (Fig. 21C, arrow). However, within tumor tissues the intracellular 
domain (Red) is often seen in the absence of the extracellular domain (Green) 
indicating that the extracellular domain of ALCAM was shed (Fig. 21C, arrow 
head). In gastric cancer, entire glandular structures appear to lack staining for the 
extracellular domain while others are fully positive (Fig. 21Ci). This all-or-none 
staining for the extracellular domain suggests that ALCAM-shedding is activated 
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at a macroscopic level within the tissue architecture of the stomach. In colorectal 
carcinoma tissue ALCAM staining is more heterogeneous with small populations 
of cells within the same histological structure exhibiting different levels of staining 
for the ALCAM extracellular domain (Fig. 21Cii). The irregular staining in CRC 
suggests that ALCAM shedding is occurring throughout the tumor but regulated 
at a cellular level. 
Quantitative analysis of ALCAM shedding. Previous studies evaluating AL-
CAM as a biomarker for predicting colorectal cancer patient survival have pub-
lished conflicting and inconclusive results (20,52,53,109,161,162). We postulate 
that this variability  is due to ALCAM shedding, since these studies all evaluate 
ALCAM through detection of its extracellular domain. To visualize ALCAM shed-
ding we used HPA010926 rabbit monoclonal antibody to detect the extracellular 
domain and 1G3A1 monoclonal mouse antibody  (Fig. 20) to detect the intracellu-
lar domain. Shedding of ALCAM was defined for the selected tumor area as the 
presence of the intracellular domain of ALCAM and the absence of the extracellu-
lar domain of ALCAM (Fig. 22). Immunofluorescent staining for each domain was 
completed simultaneously  on sections from paraffin-embedded colorectal cancer 
tissue which were digitally  scanned and quantitatively  assessed using ImageJ 
(Fig. 23). Shedding was defined as the loss of the extracellular domain and re-
tention of the cytoplasmic domain. Shedding data is presented graphically in Fig. 
22A and B. Quantitatively  ALCAM shedding is the fraction of detectable ALCAM 
from which the extracellular domain is absent ([Total ALCAM-Intact ALCAM]/Total 
78
79
F
ig
u
re
 2
2.
 Q
u
an
ti
ta
ti
ve
 a
n
al
ys
is
 o
f 
A
L
C
A
M
 s
h
ed
d
in
g
 i
n
 C
R
C
. 
T
he
 A
LC
A
M
 d
ua
l 
st
ai
n 
w
as
 u
se
d
 t
o 
de
te
ct
io
n 
th
e 
ex
tr
ac
el
lu
la
r 
do
m
ai
n 
(g
re
en
) 
an
d 
in
tr
ac
el
lu
la
r 
do
m
ai
n 
(r
ed
) 
of
 A
LC
A
M
 in
 n
or
m
al
 c
ol
on
ic
 m
uc
os
a 
(A
) 
an
d 
co
lo
re
ct
al
 
ca
nc
er
 (
B
).
 U
si
ng
 c
om
pu
ta
tio
na
l a
na
ly
si
s 
w
ith
 I
m
ag
eJ
, 
in
ta
ct
 A
LC
A
M
 w
as
 d
efi
ne
d 
by
 th
e
 c
o-
lo
ca
liz
at
io
n 
of
 d
et
ec
ta
bl
e 
in
tr
ac
el
lu
la
r 
do
m
ai
n 
(I
C
D
) 
an
d
 e
xt
ra
ce
llu
la
r 
do
m
ai
n 
(E
C
D
). 
A
LC
A
M
 s
he
dd
in
g
 w
as
 d
efi
ne
d
 a
s 
th
e
 d
et
ec
tio
n 
of
 A
LC
A
M
-
IC
D
 in
 t
he
 a
bs
en
ce
 o
f c
o-
lo
ca
liz
ed
 A
LC
A
M
-E
C
D
. T
he
 re
su
lts
 o
f t
hi
s 
an
al
ys
is
 p
re
se
nt
s 
A
LC
A
M
 s
he
dd
in
g
 q
ua
nt
ita
tiv
el
y 
as
 th
e
 fr
ac
tio
n 
of
 t
ot
al
 d
et
ec
ta
bl
e
 A
LC
A
M
 fr
om
 w
hi
ch
 t
he
 e
xt
ra
ce
llu
la
r 
do
m
ai
n 
is
 a
bs
en
t. 
T
hi
s 
is
 s
ho
w
n 
gr
ap
hi
ca
lly
 in
 
th
e 
la
st
 p
an
el
 w
ith
 th
e 
co
lo
rs
 y
el
lo
w
 a
nd
 te
al
 r
ep
re
se
nt
in
g 
in
ta
ct
 A
LC
A
M
 a
nd
 A
LC
A
M
 s
he
dd
in
g 
re
sp
ec
tiv
el
y.
80

	







	







 

 


%
$
 

 










 















#







	












	




"








	







	







	












	




















!














































	




 






" 

##



!





$
$





$
$





	






F
ig
u
re
 2
3.
 T
h
e
 im
ag
e 
p
ro
ce
ss
in
g 
p
ip
el
in
e 
im
p
le
m
en
te
d 
u
si
n
g 
F
IJ
I. 
Im
ag
es
 o
bt
ai
ne
d 
of
 n
or
m
al
 (
A
) 
an
d 
tu
m
or
 (
B
) 
tis
su
es
 t
hr
ou
gh
 s
ca
nn
in
g
 o
n 
th
e
 A
rio
l®
 p
la
tfo
rm
 w
er
e
 p
ro
ce
ss
ed
 t
o
 o
bt
ai
n 
th
e
 f
ra
ct
io
n 
of
 A
LC
A
M
 s
he
d.
 T
he
 o
rig
in
al
 
im
ag
es
 w
as
 s
ep
ar
at
ed
 i
nt
o
 i
ts
 i
nd
iv
id
ua
l 
co
lo
r 
ch
an
ne
ls
 a
nd
 t
hr
es
ho
ld
 v
al
ue
s 
w
er
e 
ob
ta
in
ed
 f
or
 t
he
 r
ed
 c
ha
nn
el
 
(A
LC
A
M
-I
C
D
) 
an
d
 th
e 
gr
ee
n 
ch
an
ne
l (
A
LC
A
M
-E
C
D
). 
A
 c
o-
lo
ca
liz
at
io
n 
of
 t
he
se
 t
hr
es
ho
ld
ed
 a
re
as
 w
as
 u
se
d
 to
 d
is
tin
-
gu
is
h 
in
ta
ct
 A
LC
A
M
 (
bo
th
 A
LC
A
M
-I
C
D
 a
nd
 -
E
C
D
, 
ye
llo
w
) 
fr
om
 s
he
d
 A
LC
A
M
 (
on
ly
 A
LC
A
M
-I
C
D
, 
te
al
).
 Q
ua
nt
ita
tiv
el
y 
A
LC
A
M
 s
he
dd
in
g 
is
 d
efi
ne
d 
as
 th
e 
fr
ac
tio
n 
of
 d
et
ec
ta
bl
e 
A
LC
A
M
 fr
om
 w
hi
ch
 th
e 
ex
tr
ac
el
lu
la
r 
do
m
ai
n 
is
 a
bs
en
t.
ALCAM). In normal colonic mucosa, detection of the extracellular and intracellu-
lar domains overlap extensively, demonstrating the predominant presence of in-
tact ALCAM (yellow) and little ALCAM shedding (teal) (Fig. 22A, last panel). Con-
versely, in tumor sections the intracellular domain of ALCAM remains detectable 
while the extracellular ALCAM is frequently  absent, indicating that ALCAM is 
shed (Fig. 22B, last panel).
ALCAM shedding corresponds with reduced patient survival.  Since ALCAM 
shedding is clearly elevated in tumors, we hypothesized that ALCAM shedding 
can be an accurate prognostic marker for colorectal cancer. To evaluate this, his-
tological detection of ALCAM shedding was performed on specimens from 105 
CRC patients and 12 healthy  controls (see Table 4 for patient demographics). For 
each specimen, ALCAM shedding was quantified as described for Fig. 22. For 
each patient, the mean value across three specimens was used to evaluate the 
correlation between ALCAM shedding and patient survival. ALCAM shedding is 
clearly  elevated in tissue from CRC (Fig. 24A). Shedding is already  increased in 
some stage I CRC patients  and is significantly  increased for stage II, III and IV 
patients. Indeed ANOVA analysis confirms significant elevation across the in-
creasing stages (mean fraction shed = 0.64, 0.73, and 0.89, for stage II, III, and 
IV, Fig. 24B). Moreover, ALCAM shedding was elevated in patients that died dur-
ing the course of their disease. The presence of elevated ALCAM shedding in 
stage II patients is particularly  interesting. This led us to hypothesize that patients 
with elevated ALCAM shedding have a worse outcome. 
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Characteristic Total Low ALCAM Shedding*
High ALCAM 
Shedding*
N (%) 105 50 (47.6) 55 (52.4)
Age at Dx
[Range] 63.7[10-90] 61.5 [26-89] 65.6 [10-90]
AJCC Stage (%)
I 8 (10.7) 4 (50) 4 (50)
II 66 (42.7) 35 (53) 31 (46.9)
III 25 (37.3) 10 (40) 15 (60)
IV 6 (9.3) 0 (0) 6 (100)
Sex (%)
M 52 (49.3) 27 (52)  25 (48)
F 53 (50.7) 23 (43) 30 (57)
Average ALCAM 
Shedding Score 
[Range]
0.68 
[0.011-0.99]
0.42 
[0.011-0.75]
0.89 
[0.77-0.99]
* Low and High ALC
ALCAM that is shed
AM are dicoto
 being equal t
mized across th
o 0.75.
e fraction of 
Table 4. Comparison of High and Low ALCAM Shedding colon cancer patients 
with respect to age, sex, and staging
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Figure 24. ALCAM shedding in CRC correlates with poor survival. ALCAM 
shedding was evaluated in tissue from 105 CRC patients and 12 healthy con-
trols. Scatter plots demonstrate the differences in ALCAM shedding between 
normal colonic mucosa and CRC tumors as a single population (A), stratified 
across histological stage (B), or separated according to survival (C). Kaplan-
Meier survival curves of CRC patients with high versus low ALCAM shedding 
were generated and log-rank tests performed to evaluate the correlation of AL-
CAM shedding with overall survival of patients at all stages (D), overall survival 
of stage II patients (E) or disease-specific survival of stage II patients (F). Scatter 
plots show the mean and SEM with statistical evaluation by Mann-Whitney for 
selected groups (A and C) or Kruskal-Wallis with Dunn’s multiple comparison re-
stricted to normal (B). Survival is presented as Kaplan-Meier plots with the log-
rank test used to evaluate significance.
 To evaluate the correlation between ALCAM shedding and patient outcome, 
survival analysis was performed by segregating CRC patients based on ALCAM 
expression (Fig. 24D) using a shed fraction of 0.75 to delineate “High” vs “Low” 
ALCAM shedding. When analyzing the full population of CRC patients, high AL-
CAM shedding correlated positively with worse overall survival (p=0.035, Figure 
24D). To determine if ALCAM shedding can be prognostic for early  stage dis-
ease, a univariate survival analysis was performed specifically to stage II pa-
tients. While ALCAM shedding does not correlate with overall survival in stage II 
patients (Fig. 24E), it correlates strongly with disease-related death showing sig-
nificant survival benefit in the Stage II patients with low ALCAM shedding (Fig. 
24F, p=0.01 HR=3.0). 
 Multivariable analysis was restricted to stage II patients since they were 
the emphasis of our investigation and the cohort biased to this population. Multi-
variable analysis with logistic regression of stage II patients found that ALCAM 
shedding and age at time of diagnosis were both independent predictors of over-
all survival after adjusting for gender and race (ALCAM shedding; adjusted odds 
ratio (OR), 9.972; 95% confidence interval (CI) 1.17-84.9 ; p=0.035. Age; OR, 
1.079; 95% CI, 1.027-1.133; p=0.003). An analysis of disease-specific survival 
found that only ALCAM shedding was an independent predictor of survival after 
adjusting for age at time of diagnosis, race and gender (ALCAM shedding OR, 
29.02; 95% CI, 2.165-389.08; p=0.011). Bootstrapping was performed as an in-
ternal validation to confirm these results and found that ALCAM shedding contin-
84
ued to be an independent predictor of survival in stage II patients (overall survival 
p=0.002; disease-specific survival p=0.023).
DISCUSSION
The main goal of this study was to determine if ALCAM shedding corresponds to 
patient outcome in colorectal cancer. As cancer treatments evolve towards indi-
vidualized therapies, they rely increasingly on the availability  of prognostic and 
predictive markers to determine the patient’s status and facilitate treatment deci-
sions. Some published studies evaluating ALCAM detection as a biomarker for 
CRC suggest clinical utility, but others have been inconclusive and contradictory 
(20,52,53,109,162). This ambiguity  in the literature may be explained by ALCAM 
shedding via ADAM17-mediated cleavage (83,89). We propose that ALCAM 
shedding, rather than its expression, indicates disease progression. Our dual 
stain reveals both intra- and extracellular epitopes of ALCAM and clarifies its 
prognostic value in CRC. ALCAM shedding in tissues was defined as the detec-
tion of the intracellular epitope in the absence of the extracellular domain. Using 
this novel assay, we demonstrate a strong correlation between elevated ALCAM 
shedding and poor patient outcome. Importantly, ALCAM shedding correlates 
with poor outcome in early stage disease (Stage II, Fig. 24). Thus, ALCAM is not 
merely a biomarker for disease progression but may also allow for outcome 
stratification among patients with early stage disease.
 ALCAM was originally  identified in the context of at least five distinct bio-
logies: leukocyte activation, neuronal guidance, bone development, stem cell 
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identification, and cancer progression (120). ALCAM expression is frequently 
elevated during oncogenesis. However, detection of the protein in tumor tissues 
is extremely variable. Knowing that ALCAM is shed by  the protease ADAM17 
(83), we speculated that in CRC, ALCAM is expressed and shed by ADAM17 into 
the circulation. Indeed, the irregular pattern of expression reported here for AL-
CAM was previously observed for ADAM17 in glandular tissue of early  to ad-
vanced gastric cancer (164) and colorectal cancer patients (53). Unfortunately, 
serum levels of ALCAM in controls (cancer-free age + sex-matched individuals, 
45-95ng/ml) overlap with circulating levels in CRC patients pre- or post-therapy 
(45-125 and 50-110ng/ml respectively, Fig. 16E). This compromises the accuracy 
and specificity of a blood test for ALCAM (Fig. 16) (165). Nevertheless, the lack 
of specificity for tumor-derived ALCAM detection in the circulation does not ne-
gate the fact that ALCAM shedding within the tumor tissue corresponds with dis-
ease progression.
 The detection of ALCAM shedding within the tumor tissue itself greatly  in-
creases the specificity of ALCAM as a prognostic factor. Our primary aim was to 
devise a method to stratify at-risk patients using ALCAM shedding as an indicator 
of disease progression and poor patient outcome, and not as a diagnostic tool. 
Indeed, the strong correlation between ALCAM shedding and poor patient out-
come in early stage disease suggests that molecular progression can occur in a 
cancer that appears histologically more benign.
 An important disparity becomes apparent when we correlate clinical out-
come (survival) with ALCAM gene transcription (mRNA), protein expression 
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(based on detection of intact ALCAM) and ALCAM shedding. Elevated ALCAM 
transcription is associated with poor outcome yet elevated levels of intact ALCAM 
protein (through detection of co-localized extracellular domain and intracellular 
domain) is associated with improved outcome (Fig. 25A vs. B). This disparity 
could be rectified if we consider that the extracellular domain of ALCAM is shed 
leaving the mistaken impression that ALCAM protein is lost during tumor pro-
gression. Indeed, our analysis of ALCAM shedding (summarized in Fig. 25C) 
demonstrates that ALCAM shedding rather than loss of expression corresponds 
with patient outcome. This observation can explain why  five independent evalua-
tions of ALCAM in CRC have given conflicting results (20,52,53,109,162).
 Although ADAM17 is responsible for proteolytic cleavage of several tumor-
associated proteins, few studies have analyzed ectodomain shedding for prog-
nostic purposes. Only one other study attempted to look at shedding used mono-
clonal antibodies specific for the cleavable form of ErbB4 (166), but was unable 
to look at shedding directly. The dual staining of ALCAM we presented here is, 
then, a novel approach to detect molecular behavior (shedding) rather than the 
molecular identity. Indeed, our results suggest that detection of molecular behav-
ior correlates more specifically with the disease than gene expression itself. 
Given that the disruption of ALCAM-ALCAM interactions promotes tumor cell mo-
tility  and metastasis (94,167), ALCAM shedding may predict malignant progres-
sion at a molecular level. The clinical correlation between ALCAM shedding and 
patient outcome (Fig. 24) suggests that detection of disease progression at a mo-
lecular level can predict long-term patient outcome. The presence of this correla-
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Figure 25. ALCAM mRNA, protein and shedding in colorectal cancer. 
Kaplan-Meier survival analysis contrasts CRC patients overall survival, stage II 
patient overall survival and disease-specific stage II CRC survival with high ver-
sus low ALCAM mRNA expression (A) protein expression (B) or ALCAM shed-
ding (C). Survival is presented as Kaplan-Meier plots with the log-rank test used 
to evaluate significance.
tion in early stage disease (stage II, Fig. 24) emphasizes that this molecular pro-
gression is present prior to pathological and clinical progression. Detection of this 
molecular progression allows for stratification of patients according to their risk 
for poor long-term outcome. Considering that ALCAM is altered in a number of 
malignancies (96,107,122,168), the clinical correlation of ALCAM shedding to pa-
tient outcome is likely to extend beyond CRC to other cancers.
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CHAPTER IV
CONCLUSIONS
Significance
The studies presented within this document demonstrate our work on the contri-
bution of tumor-derived ALCAM to skeletal metastasis of prostate cancer and the 
clinical relevance of its proteolytic product on patient outcome and survival. We 
hypothesized that a reduction of homotypic ALCAM interactions would disrupt 
tumor cell adhesion and enhance prostate cancer metastasis. On the contrary, 
work from Chapter II leads us to conclude that expression of ALCAM is a critical 
component of tumor metastasis to bone and survival at the secondary site. The 
work herein points out the dichotomy that exists between ALCAM expression at 
the mRNA and protein level with adding another dimensional analysis of post-
translational proteolytic regulation of ALCAM as it relates to tumor burden. These 
studies involving the regulation of ALCAM shedding by TGFβ, in particular our in 
vitro data in Chapter II, highlight the notion that the cellular microenvironment can 
act as a key modulator of tumor cell behavior. Finally, the work in Chapter III 
highlights the the use of intratumoral assessment of proteolytic cleavage as a 
novel approach to using ALCAM as a tumor biomarker in patient stratification. 
Future work will investigate the mechanisms through which ALCAM engages in 
the bone microenvironment, both in normal and pathological states. Moreover, 
investigations using the Rag1-/-:ALCAM-/- immunodeficient model in our lab will 
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help dissect the contribution of ALCAM-mediated interactions within the bone 
stroma to tumor cell behavior. Overall, this dissertation has contributed to under-
standing the multifactorial function of ALCAM in tumorigenesis and provides the 
evidence and necessary tools for future studies into the mechanism of ALCAM as 
a signaling adhesion molecule.
Preliminary Data and Future Directions
ALCAM as a mediator of apoptotic resistance
Although we demonstrate that loss of ALCAM decreases prostate tumor cell 
colonization in the bone, at least in-part, through enhanced apoptosis, the exact 
mechanism by which this happens remains unknown. One of the major hallmarks 
of cancer includes the ability of tumor cells to evade apoptosis or programmed 
cell death (169). Recent studies indicate changes in expression of cell adhesion 
molecules, including members of the IgSF, may impact apoptotic pathways in 
cancer cells (170). ALCAM is frequently dysregulated in cancer and has been 
posed to be protective of apoptosis in breast cancer (17,23,99,148). Apoptosis 
typically  involves deregulation of the p53 tumor suppressor pathway, however, 
the apoptotic effect we observed was in the PC3 p53-null cell line (171). Modula-
tion of apoptosis by  cell adhesion molecules is not a novel observation. For ex-
ample, human Jurkat T lymphotytes lacking the cell adhesion molecule, PECAM-
1, are more sensitive to UV irradiation. Moreover, in this same study, transfection 
with a Lys89Ala variant of PECAM-1, which lacks homophilic binding capacity, 
results in enhanced apoptosis. Subsequent studies in murine lung tumor cells 
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have shown enhanced apoptosis upon functional inhibition of NCAM by anti-
NCAM antibodies (172).  
 In addition to the function of the extracellular domain in cell adhesion, the 
intracellular domain of CAMs can be cleaved by gamma secretase and subse-
quently  released to elicit intracellular signaling (173). Most recently, studies of the 
intracellular domain of L1 cell adhesion molecule (L1CAM) have demonstrated 
DNA damage checkpoint response through interaction of L1CAM intracellular 
domain with NBS1, a critical component of the MRN complex in early checkpoint 
response signaling (170). While there is no known function of the short 34 amino 
acid intracellular domain of ALCAM, we have observed nuclear localization of 
ALCAM in liver hepatocytes and confocal images of lung epithelial cells using the 
intracellular domain-specific monoclonal antibody (Fig. 26). To follow up on the 
increased apoptosis results in our ALCAM knockdown in vivo experiments (Fig 
27), I completed a preliminary in vitro experiment to test if (1) intracellular ALCAM 
cleavage is necessary for protection from apoptosis and (2) determine if loss of 
ALCAM enhances apoptosis in response to TNF-alpha. Treatment with a 
gamma-secretase inhibitor in combination with TNF-alpha and cyclohexamide 
resulted in an increase in cleaved caspase-3 protein. These results suggest that 
the anti-apoptotic role of ALCAM could be mediated through cleavage of the in-
tracellular domain. (Fig 27). 
 On the other hand, it is possible that the intracellular domain of ALCAM 
may not function directly to mediate its protective effects, rather it is through indi-
rect regulation of anti-apoptotic genes. Signaling pathways that initiate down
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anti-ALCAM (extracellular) anti-ALCAM (intracellular) Merge
Figure 26. ALCAM cytoplasmic domain has a distinct distribution com-
pared to the extracellular domain. Fluorescent staining of paraffin embedded 
lung tissue with antibodies against the extracellular and intracellular domain re-
veal a unique distribution of the cytoplasmic domain. In addition to the expected 
co-localization at areas of cell-cell contact, the cytoplasmic domain is visible at 
the apical surface (white arrow, where the extracellular domain is absent), 
throughout the cytoplasm, and in the nucleus (orange arrow).
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DMSO - + - - - - - - + - - - - -
ϒ-secretase inh. - - + + - - - - - + + - - -
TNF-alpha/CHX - - - + + - + - - - + + - +
SP600125 - - - - - + + - - - - - + +
shControl shALCAM KD2
Cleaved Caspase-3
GAPDH
Figure 27. Reduced ALCAM expression results in enhanced apoptosis. PC3 
cells stably expressing a short-hairpin RNA targeting ALCAM were found to have 
increased cleaved caspase-3 as detected by Western blot compared to parental 
PC3 expressing a scrambled short-hairpin RNA. Cells were treated for 4 hrs. 
with indicated compounds: diluent control (DMSO), 1 μM InSolution gamma-
secretase Inhibitor X, 20ng/ml TNFα/10 μM cyclohexamide, 50 μM SP600125 
JNK Inhibitor. 
stream activation of apoptosis have been classified into two categories: 1. the 
intrinsic pathway involving mitochondrial stress and 2. the extrinsic pathway in-
volving TNF-α, TRAIL, and FAS-L in the engagement of death receptors (174). 
Upon activation of either pathway, there is downstream activation of caspases, a 
family of cysteine proteases that act as common cell death effector molecules. 
ALCAM is frequently  dysregulated in cancer and has been posed to be protective 
of apoptosis in breast cancer (17,23,99,175). This hypothesis is supported by in 
vitro data, whereby ALCAM gene silencing in MCF-7 tumor cells resulted in in-
creased markers of apoptosis, cleaved caspase-7 and PARP, in addition to de-
creased Bcl-2 expression (175). A known activator of apoptosis, tumor necrosis 
factor alpha (TNF-α), engages with TNFRI to promote the recruitment of signal 
transduction molecules that perpetrate cellular apoptosis (176). TNF-α also in-
duces activation of nuclear factor κB (NF-κB), which acts as a negative regulator 
of TNF-α-induced apoptosis. In breast cancer cell lines, MB-MDA-231 and MCF-
7 cells, TNF-α increases Bcl-2 mRNA and protein and this induction was de-
pendent on the p65 subunit of NF-κB (177). In a preliminary experiment utilizing 
PC3 cells stably expressing a short hairpin RNA targeting ALCAM (shALCAM 
KD3), baseline levels of cleaved caspase-3 were elevated in comparison to PC3 
shControl. Pretreatment of PC3 shALCAM KD2 cells with SP600125, a JNK in-
hibitor, in conjunction with TNF-alpha/cyclohexamide, resulted in decreased 
cleaved caspase-3 expression (Fig. 27). This result suggest that increases in 
TNF-alpha-mediated apoptosis in cells with reduced ALCAM expression is, in 
part, due to JNK activity, a known downstream effector of TNF-α-induced apop-
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tosis. (Fig. 27) (178). Taken together, we can speculate that in prostate cancer 
cells, ALCAM expression confers resistance to TNF-α-induced apoptosis possibly 
through Bcl-2 overexpression.  
Contribution of ALCAM to bone metastasis
Our data presented thus far demonstrate that tumoral ALCAM functions to in-
crease prostate tumor metastasis and to protect from apoptosis in the bone mi-
croenvironment. As ALCAM is often thought to function in the context of its cell 
adhesive function, it was surprising that a silencing of ALCAM expression in pros-
tate tumor cells led to a reduction in metastasis rather than enhanced metastasis. 
These suppositions are based on prior experiments by van Kempen and col-
leagues in which ectopic expression in BLM cells of an amino-truncated ALCAM 
construct, ΔN-ALCAM, lacking the ligand-binding domain and retaining the 
oligomerization domains, decreased cell adhesion and led to rapid metastasis in 
nude mice (94). While this study noted a reduction in primary tumor size of ΔN-
ALCAM tumor cells, it was attributed to the rapid departure of tumor cells result-
ing from disruption in cell adhesion and not a defect in proliferation or apoptosis 
(94). An alternative explanation for reduced metastasis to bone in the intracardiac 
bone metastasis model is that ALCAM knockdown tumor cells have reduced ca-
pacity to process MMP-2. In a study using a transgenic model in which the SV40 
large T antigen is overexpressed in prostatic neuroendocrine cells and MMP-2 is 
non-functional, MMP-2 “knockdout” mice had no change in primary tumor devel-
opment, however there was reduced lung metastasis and increased survival 
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(179). Considering in vitro  and in vivo data showing BLM ΔN-ALCAM and anti-
ALCAM siRNA-treated melanoma cells have severely impaired MMP-2 activa-
tion, one suspect MMP-2 activation is functionally  impaired in our models of pros-
tate tumorigenesis (93). These data support the notion that MMPs, specifically 
MMP-2, could account for no alteration in primary tumor growth, but enhanced 
metastasis (Fig 10C-F & 11).
 Although elevated apoptosis was evident in the ALCAM knockdown tumor 
cells, tumor take was not diminished in our intratibial model. This observation 
suggests while our intracardiac experiments aimed to address the role of ALCAM 
in metastasis to bone, it was not possible to tease apart ALCAM’s role in extra-
vasation versus colonization and expansion at the secondary site. In studies of 
ALCAM requirement for trans-endothelial monocyte migration, treatment with 
blocking ALCAM antibodies resulted in inhibition of trans-endothelial migration of 
monocyte lines (150). Moreover, confocal analysis of ALCAM in activated mono-
cytes revealed localization of ALCAM at endothelial junctions. In the presence of 
ALCAM-Fc or treatment with anti-ALCAM antibodies in in vitro trans-endothelial 
cell assays, THP1 monocytes have a 50% and 70% reduction in migration, re-
spectively. Monocytes do not express CD6, the heterotypic binding molecule of 
ALCAM, thus it is reasonable to conclude that homotypic ALCAM-ALCAM inter-
action is responsible for ALCAM-mediated trans-endothelial migration in mono-
cytes. Taken together with our PC3 intracardiac studies where ALCAM knock-
down in the tumor cells result in a reduction in tumor incidence, these results 
suggest additional levels of complexity  of ALCAM’s function in tumor progression 
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in which the extracellular domain of ALCAM participates in tumor cell trans-
endothelial migration. 
 While down regulation of ALCAM expression in PC3 prostate tumor cells 
was not sufficient to affect invasion or metastatic dissemination to soft tissue, me-
tastasis to bone was decreased (Fig 10). Direct inoculation in vivo of ALCAM 
knockdown tumor cells into the tibia was did not result in a significant reduction in 
tumor incidence compared to the intracardiac tumor model (Fig. 11). Though pro-
liferation and apoptosis studies determined smaller tumor occupancy in the AL-
CAM knockdown tumors, we cannot exclude the role of ALCAM in trans-
endothelial migration to mediate osteotropism in our intracardiac model. Our cur-
rent work using the orthotopic, intracardiac and intratibial models do not ade-
quately  address the extravasational component in tumor metastasis. We can 
speculate that there is a dual role for ALCAM in metastasis to bone. Though not 
quantitatively assessed, it was noted in our intracardiac injection experiments 
prior to tumor cell inoculation, that ALCAM KD cells had increased clustering. 
While the loss of ALCAM may affect trans-endothelial migration, it is also possi-
ble that compensatory increases in other related cell adhesion molecules, could 
result in increased clustering and decreased metastasis in our intracardiac 
model. in vitro (Fig. 4A), analysis of shed ALCAM, regardless of overall total cel-
lular ALCAM expression, reveals that SDF-1, PDGF, and BMP2 induce ALCAM 
shedding from the cell surface (Fig. 30). Future studies using the bone specific 
isolates, BS159 & BS473, can help  determine if bone metastatic cells are selec-
tively responsive to shed ALCAM after treatment with these cytokines.
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ALCAM as a marker of bone metastasis
To determine if TGFβ is the predominant driver of ALCAM ectodomain shedding in 
the bone microenvironment, we performed longitudinal analysis of serum ALCAM in 
tumor-bearing mice. We tested serum levels of tumor-derived ALCAM pre- and post-
treatment with a TGFβ neutralizing antibody, 2G7, compared to matched control 
IgG2a (Fig. 28).The tumor size selection for treatment was based on previous ex-
periments comparing tumor size with serum levels of shed ALCAM. Contrary  to our 
hypothesis, acute inhibition of TGFβ with 2G7 did not result in any significant 
changes in shed ALCAM (Fig. 28 B&C). This may be due to several factors including 
the possibility  that ADAM17 activity  is not exclusively activated in the bone microen-
vironment by TGFβ. Subsequent in vitro analysis of ALCAM shedding by ELISA 
shows increased baseline ectodomain shedding of ALCAM in PC3 bone meta-
static clones versus parental PC3 shControl (Fig. 29). In addition, BS-159 and 
BS-473, the highly aggressive in vivo-passaged PC3 bone-metastatic cell lines 
(Fig. 30), no longer increase ALCAM shedding in response to TGFβ  (Fig. 29C), 
confirming our results that in vivo inhibition of TGFβ in bone metastasis in unable 
to abolish ALCAM shedding. In the bone microenvironment, it is possible TGFβ  is 
no longer the main driver of ALCAM shedding. It is possible there are other driv-
ers of ALCAM expression and shedding. These include NFkappaB which, 
through upstream signaling of SDF-1, is a key chemokine in the promotion of os-
teolytic lesions and maintenance of HSC in endosteal niche (180,181). While our 
data in Chapter II have shown that TGFβ is the predominant cytokine responsible 
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Figure 28. Inhibition of TGFβ  does not decrease circulating serum tumor-
derived ALCAM (A) In vitro luciferase expression of mink lung epithelial cells 
stably expressing a plasminogen activator inhibitor–1/luciferase reporter (PAI-1/
luciferase reporter; kind gift from the lab  of Harold L. Moses) treated with the in-
dicated combinations of 10ng/ml of TGFβ, 2G7 neutralizing pan-TGFβ IgG2, 
and control IgG2, 12CA5. Treatment with 2G7 had an blunted luciferase re-
sponse to TGFβ validating 2G7 effectiveness. (B)  Serum human/tumor-derived 
ALCAM levels did not respond to inhibition of TGFβ as measured by ELISA in 
PC3-luc tumor-bearing mice at 4 weeks post-intratibial innoculation and 2 days 
post treatment with PBS (n=8), 2G7 (n=8), or 12CA5 Control IgG2 (n=8). (C) 
Quantitation of percent change in serum ALCAM from (B). 
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Figure 29. Elevated baseline ALCAM shedding and decreased sensitivity to 
TGFβ in PC3 bone metastatic subclones. (A) Overall ALCAM total protein ex-
pression; ng ALCAM/μg total protein. Levels in PC3-luc shControl parental, 
PC3-luc chest tumor isolate (C-467), PC3-luc skeletal mets (BS159 & BS473) 
were measured by ELISA. (B)  Quantitation of mean shed ALCAM levels (not 
normalized to overall ALCAM total protein expression) in conditioned media of 
PC3-luc shControl, C-467, BS159 and BS473 tumor cell lines. (C) Percent in-
crease of shed ALCAM relative to total protein expression in cells treated with 
10ng/ml of TGFβ for 48hrs.
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Figure 30. Bone microenvironment-associated soluble factors provoke 
ALCAM shedding in vitro. ELISA analysis of ALCAM shedding, pg/ml, in con-
centrated conditioned media of PC3 cells treated with indicated exogenous cy-
tokines
for ALCAM shedding in vitro (Fig. 4A), analysis of shed ALCAM, regardless of 
overall total cellular ALCAM expression, reveals that SDF-1, PDGF, and BMP2 
induce ALCAM shedding from the cell surface (Fig. 30). Future studies using the 
bone specific isolates, BS159 & BS473, can help  determine if bone metastatic 
cells are selectively responsive to shed ALCAM after treatment with these cytoki-
nes.
 In establishing an alternative immunodeficient model for bone metastasis 
(Fig. 31-32), we isolated several aggressive bone specific clones through se-
quential in vivo passaging in Rag1-/- mice (Fig. 31-32). Upon isolation of BS159 
10-week post-intracardiac injections of PC3-luc cells into Rag-/- mice, cells were 
cultured and re-injected into Rag-/- mice to produce the BS473 cell line. It is of 
note, that re-injection of BS159 into Rag-/- mice resulted in accelerated and en-
hanced osteolytic tumor burden, with endpoint for the BS159 isolate reached at 4 
weeks post-intracardiac injections versus 12 weeks for the parental line. Mean 
levels of shed ALCAM comparing parental PC3 shControl with the chest tumor 
isolate (C-467) and bone-specific isolates (BS159 & BS473), though not statisti-
cally significant, indicate a dose increase in ALCAM shedding specific to the ag-
gressiveness of bone specific clones (Fig. 29C).
 The majority  of publications concerning ALCAM shedding in the clinical set-
ting correlate serum levels with advanced stage disease; however, its temporal regu-
lation following tumor inoculation suggested it may have a physiologic role in tumor 
progression. Furthermore tumor-derived ALCAM shedding, not host-derived (Fig. 
33C) is significantly correlated with both lesion area and total number of bone le-
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Figure 32. Analysis of bone lesions formed by PC3 in Rag1-/- after in-
tracardiac injection. (A) Representative luciferase image of PC3-luc tumor-
bearing Rag1-/-; matching x-ray images from lesions present in mandible (I), 
humerus (II) and femur and tibia (III). (B) Representative mandible microCT im-
ages of osteolytic tumor burden in PC3-luc tumor-bearing mice (top) versus con-
trol PBS-injected (bottom) 
sions per animal (Fig. 33A&B). The endogenous levels of ALCAM shedding was en-
hanced in tumor cells residing in the bone versus the orthotopic site (Fig. 29B & 
33D), suggesting a microenvironmental contribution to the proteolytic shedding of 
ALCAM during the tumor progression to bone.
 In collaboration with Dr. Julie Sterling, we confirmed that tumor ALCAM shed-
ding is elevated in mice bearing skeletal metastases (Fig. 34A). Though ALCAM 
shedding correlates with tumor burden, it is particularly indicative of tumors in 
bone. Treatment with Zoledronic Acid (ZA) prevents both tumor growth and circu-
lating levels of tumor-derived ALCAM (Fig. 34B). We confirm that elevated AL-
CAM shedding correlates with tumor growth and not to general wound repair be-
cause mice recovering from a full-thickness skin wound (Fig. 7B) or acute LPS 
administration (Fig. 7C) do not exhibit elevated ALCAM levels. Collectively, these 
data suggest that ALCAM shedding may act as an clinically  relevant marker of 
skeletal metastasis and response to therapy.
ALCAM endosteal niche competition 
While we have convincing data that ALCAM expression is important in the osteo-
tropism and survival of tumor cells in the bone, (Figure 12) further work is neces-
sary  to fully elucidate the mechanisms involved. Given the proclivity of prostate 
tumor cells to metastasize to bone and contribute to disease morbidity (Coleman, 
2006), it would be beneficial to investigate ALCAM in the context of post-
dissemination survival and niche occupancy of PCa cells and their ability to co-op 
the hematopoietic niche. Molecular crosstalk between HSCs and osteoblasts in-
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Figure 33: ALCAM shedding correlates with bone lesion number and area. 
Circulating ALCAM levels were monitored longitudinally in mice bearing PC3-luc 
tumor cells inoculated via intracardiac injection in Rag1-/- mice.(A)  Circulating 
levels of soluble tumor-derived ALCAM correlated with total number of bone le-
sions R2=0.7685 (B) Circulating levels of soluble tumor-derived ALCAM corre-
lated with total number bone lesion area R2=0.8146 (C) Circulating levels of 
soluble host-derived ALCAM correlated with total number of bone lesions (D) 
Amount of shed ALCAM relative to cell number in PC3 cells orthotopically im-
planted into the prostate or injected via intracardiac route.***p<0.001 (Mann-
Whitney test) Each point reflects mean of duplicate measurements ±  SD. Each 
line and corresponding R2 represents a best fit linear regression analysis. 
Figure 34. Shedding of tumor-derived ALCAM shedding is detectable and 
responsive to zolendronate in tumor bearing animals. (A) Tumor-derived se-
rum ALCAM as measured by ELISA is readily  detected in endpoint studies of 
mice bearing MDA231 tumors in an intracardiac, intratibial, and orthotopic 
(mammary fat pad) models. Tumor-derived ALCAM corresponds to tumor burden 
in both intracardiac (occupancy %) and mammary fat pad (tumor volume) mod-
els. (B) Serum tumor-derived ALCAM in an intracardiac model of MDA231 is in-
dicative of treatment response with Zolendronate wherein treated animals lacked 
both serum ALCAM and detectable tumor-induced bone disease. 
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volves cell adhesion molecules that mediated extracellular matrix interactions, in 
addition to cell-cell interactions, both heterotypic and homotypic interactions. 
These interactions facilitate the maintenance of physical proximity of HSCs to the 
endosteal bone-marrow niche, but also participate in signaling that promotes 
HSC quiescence (180,182). 
 In the context of ALCAM, the terminal domain (D1) is required for homotypic 
interactions. In CHO cells transfected with full length ALCAM, the addition of exoge-
nous soluble ALCAM reduces cell aggregation in a dose-dependent manner, sug-
gesting that soluble ALCAM is able to compete and disrupt endogenous homotypic 
interactions (24). Recently, researchers subdivided osteoblast-enriched ALCAM 
(+) Sca (-) cells from bone marrow endosteal cells. These cells highly express 
multiple cell adhesion molecules and significantly upregulate homing and cell-
adhesion related genes in HSCs (74). Initial observations have noted that circu-
lating HSCs in prostate cancer patients have been an indicator of bone metasta-
sis, and that prostate cancer cells inoculated into bone marrow remain dormant 
and resistant to drug treatment (183). HSCs continuously migrate from the bone 
marrow to the blood and back (184,185). However, in a seminal study by Shio-
zawa et al, the authors were able to show co-transplanted prostate cancer cells 
(PC3 & C42) and hematopoietic stem cells (HSCs) transplanted into NOD/SCID 
mice compete for the endosteal niche (186). Further experiments were com-
pleted using a novel vossicle assay in which osteoblasts were depleted through 
transgene activation. In the absence of mature osteoblasts, PC3 prostate tumor 
cells directly inoculated into the vossicles were unable to grow (186,187). This 
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was in part due to enhanced apoptosis, suggesting that prostate cancer growth is 
dependent on the presence of osteoblasts in the endosteal niche for colonization. 
 Preliminary investigations from our lab  (data not shown) characterizing 
lineage differentiation in ALCAM-/- mice indicate a increase, yet not significant, in 
adipocyte differentiation and decreased osteoblast number. While further investi-
gation is warranted, these results suggest that ALCAM is important in the differ-
entiation of osteoblasts, an important component of prostate cancer colonization 
to bone. Similar to the in vivo competition assay  with HSCs and prostate cancer 
cells, one could expand to include the contribution of ALCAM in competition of the 
endosteal niche. In a study characterizing fetal and adult hematopoietic tissue, 
expression of ALCAM in CHO cells conferred homophilic adhesion that could be 
competed with a soluble recombinant ALCAM-Fc fusion protein. These data sug-
gest a role for ALCAM in the adhesion of stem cells and progenitor cells to them-
selves or to other ALCAM+ supportive cells in the microenvironment (71). One 
could pose a model, as it is related to our in vivo studies with PC3 tumor cells 
which have high levels of ADAM17 expression and ectodomain shedding of the 
extracellular domain of ALCAM, substantial amounts of soluble ALCAM gener-
ated by  tumor cells can disrupt HSC adhesion to endosteal niche thereby serving 
a dual role that includes: 1.) promoting tumor cell occupancy of endosteal stem 
cell niche and 2.) promote differentiation of HSC to osteoblastic and osteoclast 
for induction of vicious cycle.
 We have characterized a bone metastasis model in Rag1-/- immunodefi-
cient mice, isolating bone specific, highly aggressive prostate and breast meta-
110
static clones (Fig. 31-23). One particular advantage of using this model is the re-
productive robustness in breeding and maintaining homozygous mating pairs . In 
doing so, Rag1 -/-/ALCAM  -/- mice have been generated to study the impact of 
host-derived ALCAM on tumor cell metastasis to bone. In an effort to further un-
derstand the role of ALCAM in the HSC  niche, we could potentially utilize Rag1 
-/-/ALCAM  -/- mice to determine if a host-derived ALCAM is critical for HSC  homing 
or colonization in the endosteal niche. Similar experiments can be done, 
whereby, wild type HSCs and prostate tumor cells are co-injected, and we can 
determine directly if there is decreased occupancy of HSCs in the endosteal 
niche and numbers of circulating HSCs. These future experiments will lead to a 
greater understanding of ALCAM’s functional role in the tumor bone stem cell 
niche. 
Concluding Remarks
The data presented within dissertation demonstrate the impact of ALCAM in 
prostate cancer progression and human colorectal cancer patient outcome 
through genetic, biochemical analyses, animal models and through using novel 
dual-immunohistochemistry of human tissue. Despite the clinical relevance and 
its role in diverse cellular processes, the precise function of ALCAM in prostate 
cancer is largely  unknown. Our work presented herein, has advanced our under-
standing of ALCAM as a serum biomarker and functionally its role in metastasis. 
Furthermore, in our clinical studies, the detection of intratumoral regulation of 
ALCAM proteolytic cleavage can be a predictive measurement of patient out-
come. The diversity of ALCAM functions in neuronal migration, immune modula-
111
tion and hematopoietic maintenance represent several pathways that can be ex-
ploited by  tumor cells to promote metastasis and growth. We anticipate new in-
sights into the dynamic relationship  between the extracellular adhesive functions 
and intracellular signaling role will emerge in future mechanistic studies of AL-
CAM. While it is suspected that ALCAM function may be context and cell de-
pendent, insight will lead to a broader application to investigating the intracellular 
signaling capacity of cell adhesion molecules. While the adhesive function is im-
plied of cell adhesion molecules, subsequent regulation of intracellular localiza-
tion and signaling have largely been understudied. Further investigation is war-
ranted to understand the full contribution of ALCAM to cancer and our ability to 
co-opt this participation towards improved therapy. 
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